Outpatient regimens to reduce COVID-19 hospitalizations: a systematic review and metaanalysis of randomized controlled trials.

David J. Sullivan M.D.¹
Daniele Focosi M.D.²
Daniel Hanley M.D.³
Mario Cruciani, MD⁴
Massimo Franchini, M.D.⁴
Jiangda Ou M.S.³
Arturo Casadevall M.D., Ph. D.¹
Nigel Paneth M.D., M.P.H.⁵

Corresponding author: David Sullivan, 615 N. Wolfe St Rm W4606, Baltimore MD 21205. Tel 410 502 2522, fax 410 955 0105. E-mail <u>dsulliv7@jhmi.edu.</u>

Title 15 words Abstract word count 150 Main text- 4271 3 tables and 7 figures

Abbreviations: CCP: COVID-19 convalescent plasma; mAb: monoclonal antibody. RCT: randomized controlled trial; VOC: variant of concern.

Keywords: small molecule antivirals; convalescent plasma; monoclonal antibody; COVID-19; outpatients; randomized controlled trial.

¹Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, MD USA,

²North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

³Johns Hopkins University School of Medicine Department of Neurology, Brain Injury Outcomes Division, Baltimore, MD, USA.

⁴Division of Hematology, Carlo Poma Hospital, Mantua, Italy.

⁵Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, MI, USA.

Abstract ______3 Introduction ______4 Trial populations 5 Seropositivity and timing from symptom onset ________6 Efficacy at preventing hospitalization 6 Efficacy at symptom resolution 8 Methods 10 Literature search ________11 Declaration of interests 12 Contributors 12 Funding 12 References 13

Abstract

During pandemics, out-of-hospital treatments reduce the health system burden. Controversies persist regarding the best treatment options for COVID-19 outpatients at risk for hospitalization. We assembled data from 47 randomized controlled trials investigating 51 distinct interventions in more than 60,000 outpatients until October 2022 with the endpoint of hospitalization. These trials, largely performed in unvaccinated cohorts during pre-Omicron waves, mostly targeted populations with at least one risk factor for COVID-19 hospitalization. Grouping by class, the COVID-19 convalescent plasma (CCP) (OR=0.69 [95% CI=0.53 to 0.9]), anti-Spike monoclonal antibodies (OR=0.32 [95% CI=0.24-0.42]) and small molecule antivirals (OR=0.57 [95% CI=0.3-1.09]) each had comparable efficacy for hospital relative risk reduction dependent on intervention dose and timing. Repurposed drugs had lower efficacy. The recent Omicron sublineages (XBB and BQ.1.1) in vitro resistance to monoclonal antibodies suggests a pressing need to reevaluate CCP recommendations for COVID-19 outpatients at risk for hospitalization, especially in constrained medical resource settings.

Introduction

By late October 2022 the world had recorded over 630 million cases and more than 6.6 million deaths from COVID-19. Hospitalization rates are about 6% in the US, where from August 2020 to October 2022, nearly 5 million individuals were hospitalized for COVID-19. A pronounced spike in hospitalizations for COVID-19 in the US took place in the first two months of 2022 with the introduction of the Omicron variant of concern (VOC). Vaccination boosts have substantially reduced the risk of hospitalization and death, but outpatients at risk still require early treatment to avoid disease progression to hospitalization.

The risk of hospitalization can be reduced by antivirals of different classes (COVID-19 convalescent plasma (CCP), anti-Spike monoclonal antibodies (mAbs) or small molecules) or supportive care drugs (which are largely repurposed). Randomized controlled trials (RCTs) in outpatients have tested therapeutic agents against placebo or standard of care, but no RCT has been conducted comparing the main classes of outpatient treatments. CCP was first administered to hospitalized patients across the world in March 2020, a few weeks after the pandemic began¹, but was initially FDA restricted to inpatient use in the US.

The first outpatient treatments for COVID-19 authorized by the FDA were anti-Spike mAbs (bamlanivimab, bamlanivimab plus etesevimab^{2, 3} or casirivimab plus imdevimab⁴) approvals that preceded the introduction of mRNA vaccines^{5, 6}. While many small molecules were repurposed as antivirals during the early stages of the pandemic, oral antivirals developed against SARS-CoV-2 for outpatients were not authorized and available until December 2021, when nirmatrelvir/ritonavir⁷ and molnupiravir⁸ were approved. The following month, intravenous remdesivir was also approved for outpatient use⁹. On December 2021, nearly two years after the first use of CCP, the FDA approved CCP outpatient use, but only for immunosuppressed patients^{10, 11}.

To date no head-to-head RCT has ever compared antiviral treatment options for COVID-19 outpatients (with the few exceptions of Eli Lilly comparing bebtelovimab to bebtelovimab+bamlanivimab+etesevimab¹² or metformin, ivermectin and fluvoxamine in COVID-OUT¹³), making treatment choices difficult. We assembled RCTs of different therapies all sharing hospitalization as an endpoint. A literature search of MEDLINE (through PubMed), medRxiv and bioRxiv databases was carried out inclusive of RCTs published from March 2020 to October 2022 summarized in the PRISMA chart (Figure 1). This systematic review and meta-analysis of RCTs of outpatient therapy for COVID-19, compared outcomes, taking into account risk factors for progression, dosage of the intervention, time between onset of symptoms and treatment administration, and predominant variants of concern at the time of the interventions.

Results

We reviewed in detail 47 distinct outpatient RCTs (51 different interventions), conducted from March 2020 to October 2022, across waves sustained by different SARS-CoV-2 variants of concern (VOC) and different vaccination periods. We focused on four different therapeutic categories – CCP, anti-Spike mAbs, small molecule antivirals and repurposed drugs.

Five large-scale outpatient RCTs investigating CCP have been published. A successful RCT from Argentina¹⁴ was followed by another RCT (C3PO-SIREN) halted at 511 participants after the data safety monitoring board (DSMB) determined "futility" before completion¹⁵. The third RCT in Spain (CONV-ERT) involved methylene blue-treated CCP¹⁶, raising concern about interference with Fc-dependent antibody function¹⁷, and the fourth was a large RCT in the USA (CSSC-004)

¹¹. A fifth RCT was run in The Netherlands (Cov-Early), originally published as combined analysis with the Spanish RCT¹⁸ and later as individual data¹⁹.

Eight anti-Spike mAb RCTs (bamlanivimab², bamlanivimab/ etesevimab³, casirivimab/ imdevimab phase 1/2²⁰ and phase 3²¹, sotrovimab²², regdanvimab²³, bebtelovimab¹² and tixagevimab–cilgavimab²⁴) led to FDA emergency use authorizations (EUA), with regdanvimab²³ approved in Europe only and bebtelovimab approved in US only.

Of 11 outpatient RCTs of small molecule antivirals - oral molnupiravir^{8, 25, 26}, oral nirmatrelvir/ritonavir⁷ and intravenous remdesivir²⁷ led to EUAs. Other antivirals studied by RCTs included peginterferon lambda^{28, 29, 30}, sofosbuvir/daclatasvir³¹, favipiravir³² and lopinavir/ritonavir³³.

Additionally, 15 repurposed drugs tested in 23 outpatient RCTs were included in our analysis for context: metformin¹³, fluvoxamine^{13, 34, 35}, ivermectin^{13, 36, 37, 38}, hydroxychloroquine^{33, 39, 40, 41, 42}, nitazoxanide⁴³, colchicine⁴⁴, niclosamide⁴⁵, four antithrombotics-aspirin, apixaban⁴⁶, sulodexide⁴⁷, enoxaparin^{48, 49}, inhaled ciclesonide⁵⁰, the herbal mixture Saliravira⁵¹, azithromycin^{52, 53}, and resveratrol⁵⁴.

GRADE

The 5 CCP RCTs had a high GRADE (Supplementary Table 1). Most information is from results at low risk of bias or with some concerns, but unlikely to lower confidence in the estimate of effect. The GRADE for anti-Spike mAbs RCTs was moderate (downgraded for risk of bias (ROB)). The RCTs for small molecule antivirals had a GRADE level low for inconsistency (I²=81) and ROB. The RCTs for repurposed antiviral drugs had a moderate GRADE score for ROB. All four trial classes showed reduced rates of hospitalization for each group. The ROB independently was evaluated by NMA-COVID-19 for most all of the RCTs (Supplementary Figure 1).

Trial populations

The 47 RCTs (51 interventions) ranged in duration between 1 and 16 months, averaging 9, 4, 5 and 7 months for the CCP, anti-Spike mAbs, small molecule antivirals and repurposed drugs, respectively (Figure 2, Table 1, Supplementary Table 2). 24 studies were completed in the pre-Alpha VOC period, with 14 encompassing either the Delta or Omicron wave only. All cause (n=30) or COVID-19 related (n=21) admissions by day 28-30 was the hospital endpoint for most RCTs (9 RCTs measuring at day 14-23, 1 at day 45 and 2 at day 90), excepting the single Argentinean CCP RCT, which used severe respiratory distress as a proxy for hospitalization¹⁴ (Table 1). Of more than 60,000 participants enrolled, 55% were in RCTs of small molecule antivirals, 28% in RCTs of repurposed antiviral drugs, 12.5% in RCTs of anti-Spike mAbs and 4.5% in CCP RCTs. Nearly half of all recruited outpatients were from the single molnupiravir-PANORAMIC RCT, which recruited 25,000 participants²⁵.

Age and ethnicity

The median age of participants was about 50 years. The CCP group had a nonweighted trial average of median age equal to 58 years, while the anti-Spike mAbs, small molecule antivirals and repurposed drug groups younger average of median age was equal to 45 to 48 years. Most RCTs

had more women than men, and 84% of all RCT 60,043 participants had Caucasian ethnicity (Table 1, Supplementary Table 2).

Risk factors for COVID19 progression

The individual RCTs differed in the percentage of participants with risk factors for progression to severe COVID-19. Of the 37 RCTs reporting aggregated hospitalization risk factors, ten had 100% of participants with at least one hospitalization risk factor, while 5 had less than 50%. The Bebtelovimab placebo-controlled RCT explicitly focused exclusively on low-risk individuals ¹². Individual risk factors like diabetes mellitus occurred in 10 to 20% of participants within most RCTs. Obesity with BMI over 29 averaged near 40% of RCT participants in the 4 therapy groups after excluding the large single 25,000 molnupiravir-PANORAMIC RCT with 15% of participants over 30 BMI (Table 1) ²⁵.

Seropositivity and timing from symptom onset

Of 18 RCTs reporting seropositivity rates at baseline, 11 had < 25% screening seropositivity (Table 1, Figure 2). The molnupiravir-PANORAMIC RCT was an outlier, with 98% seropositives²⁵. All but one⁴⁴ of the RCTs enrolled within 8 days (median) of symptom onset. In RCTs of anti-Spike mAbs and small molecule antivirals, median time from illness onset to intervention was 3.5 to 4 days (Figure 3, Table 1, Supplementary Table 2). CCP and repurposed antiviral drug RCTs enrolled within 4.5 to 5.1 days from symptom onset.

Geography and time period

The CCP RCTs were conducted in the USA^{11, 15}, Argentina¹⁴, Netherlands¹⁸ and Spain¹⁶ (Supplementary Table 2). The anti-Spike mAb RCTs all had a USA component, but were largely centered in the Americas except for the sotrovimab RCT, which took place in Spain²². Many of the repurposed drugs and nirmatrelvir/ritonavir RCTs recruited worldwide⁷.

Four of the five CCP RCTs (COV-Early¹⁸, CONV-ERT¹⁶, Argentina¹⁴ and C3PO¹⁵), and all eight anti-Spike mAb RCTs took place in the setting of the D614G variant and the Alpha VOC (Figure 2). By contrast, most of the molnupiravir, nirmatrelvir/ritonavir⁷ and interferon lambda RCTs were conducted in the setting of the Delta VOC. The ivermectin³⁶ and fluvoxamine³⁴ RCTs ended as the Delta VOC wave began in August 2021. The remdesivir RCT spanned D614G, Alpha and Beta VOC but missed Delta²⁷. The CSSC-004 RCT of CCP was the longest RCT reviewed, spanning periods characterized by D614G to Delta VOC infections¹¹.

Efficacy endpoints

Efficacy at preventing hospitalization

Because inclusion criteria varied across the RCTs, the power to detect a difference in hospitalization rates varied across studies. Three CCP RCTs had higher control arm hospitalization rates (11% - 31%) than all other antiviral RCTs, indicating that they studied sicker populations. ¹¹ (Table 2 and Figure 4). The six mAb RCTs had hospitalization rates in the controls of 4.6-8.9%, the same range as CSSC-004¹¹ (6.3%). Control hospitalization rates in the molnupiravir-MOVE-OUT⁷, nirmatrelvir/ritonavir⁷ and remdesivir²⁷ RCTs, all agents that obtained FDA EUAs, ranged from 5.3% to 9.7%. Low hospitalization rates were found in RCTs that had many vaccinees (metformin-COVID-OUT – $3.2\%^{13}$) or in which most participants were seropositive (molnupiravir-PANORAMIC – 0.8%). Low control arm hospitalization rates were also found in

two mAb RCTs – the bebtelovimab trial $(1.6\%)^{12}$ and REGN-CoV phase 1/2 (<2%), with the bebtelovimab RCT focusing on low-risk patients 12

Examining RCTs by agent class, statistically significant relative risk reductions in hospitalization were found in two of 5 CCP RCTs, 5 of 8 anti-Spike mAb RCTs, 4 of 11 small molecule antiviral RCTs, but just 2 of 23 repurposed drug RCTs (Table 2). Considering effect size, CCP efficacy in preventing hospitalization or progression was about 50% in both the Argentinean¹⁴ and in CSSC-004 RCTs¹¹ and 36% and 31% in COV-Early¹⁸ and C3PO¹⁵. Except for the bebtelovimab RCT (2 hospitalizations in each arm¹²), anti-Spike mAb RCTs reduced the risk of hospitalization by 69-80% (average 75%). Two of the three small molecule antiviral drugs (remdesivir²⁷ and nirmatrelvir/ritonavir⁷) showed very high levels of relative risk reduction - 86% and 88% respectively - but molnupiravir reduced risk of hospitalization by only 30%⁷ (no reduction in the PANORAMIC RCT²⁵), and the combination of lopinavir/ritonavir was associated with a non-significant increase in risk of hospitalization³³.

Among RCTs of repurposed drugs, all except metformin (57%) and sulodexide (40%), showed small and non-significant relative risk reductions of hospitalization - 11% for ivermectin³⁶, 20% for colchicine⁴⁴, 21% for fluvoxamine³⁴ and 24% for hydroxychloroquine³³. The RCT of nitazoxanide⁴³ found one hospitalization among 184 treated participants compared to five hospitalizations among 195 controls, far too few events to achieve significance.

In the pooled meta-analysis by class group, the CCP RCTs had a fixed effect OR of 0.69 (95% CI=0.53 to 0.9) with moderate heterogeneity (I^2 =43%), the anti-Spike mAbs had a fixed effect OR of 0.32 (95% CI=0.24-0.42) with low heterogeneity (I^2 =0%), the small molecule antivirals had a random effect OR of 0.57 (95% CI=0.3-1.09) with high heterogeneity (I^2 =80%) and the repurposed drugs had a fixed effect OR of 0.77 (95% CI- 0.68-0.88) with low heterogeneity (I^2 =4%) (Figure 5, Supplementary Table 3). The meta-analysis of all interventions had a random effect OR of 0.62 (95% CI=0.51-0.74) with high heterogeneity (I^2 =58%) (Supplementary Figure 2).

Overall, RCTs proved the value of early treatment. Ten RCTs by design began outpatient treatment within the 5-days window and an eleventh reported point estimate numbers. Relative risk reduction in hospitalization was 73% (OR=0.2, 95%CI-.06-0.71) in recipients of higher dose or higher antibody titer CCP in Argentina transfused within 3 days, ¹⁴ and was 80% (OR=0.18, 95%CI-.07-0.49) in participants treated within 5 days of symptoms in CSSC-004 ¹¹ (Figure 6), which is comparable to nirmatrelvir⁷ (OR=0.12, 95%CI-.06-0.24) and sotrovimab (OR=0.19, 95%CI-.08-0.46) therapy within 5 days of symptom onset (Supplementary Table 3).

The final certainty of the available evidence with GRADE assessment (Supplementary Table 1) showed high level of certainty within CCP trials, moderate certainty with mAbs, and low certainty with small molecule antivirals and repurposed drugs. The heterogeneity amongst all of the outpatient trials with hospitalization as an endpoint measured by the I² statistic is 58%, with p-value < 0.01. The main reason for downgrading individual studies was imprecision, related to small number of participants and the wide confidence intervals around the effect, followed by ROB (Supplementary Figure 1). In the cumulative analysis, small molecule antivirals were downgraded to low certainty of evidence because of ROB (some/high ROB in 4 RCTs) and inconsistency (due

to high heterogeneity), while repurposed drugs were downgraded to low certainty due to ROB (some/high ROB in 5 of the 11 comparisons) and indirectness (due to large difference in mechanism of action of the included drugs). Anti-Spike mAbs were downgraded to moderate certainty due to ROB (in 4 of the 8 included RCTs, ROB for the outcome hospitalization was judged of some concern). Of note, we could not find concerns in any of the GRADE factors for CCP RCTs and therefore they were graded as high level of certainty. Funnel plot analysis shows a low risk of publication bias except for the anti-Spike mAbs, for which either the efficacy of high dose antibodies or non-reporting bias are plausible explanations (Supplementary Figure 3).

Efficacy at reducing mortality

While several RCTs showed fewer deaths in the treatment arm, no outpatient study was powered to compare differences in mortality. Cumulatively, the two effective CCP RCTs (Argentine¹⁴ and CSSC-004¹¹) recorded 7 deaths in controls and 2 in the treatment arm, but C3PO reported 4 more deaths in the CCP arm¹⁵. Cumulatively, the anti-Spike mAbs RCTs had 21 deaths among controls and 4 in the intervention arm (Supplementary Table 4). The 3 emergency-authorized small molecule antiviral RCTs experienced 22 deaths in the control groups and 1 in the intervention groups while the total for all small molecule antiviral RCTs was 28 in the controls and 7 in the interventions. The repurposed drugs RCTs recorded 72 deaths in the control groups and 53 in the intervention groups. Because of the low rate of deaths during trials the absolute risk reductions amongst the 4 antiviral classes are all below 1% corresponding to relative risk reductions of 20%, 84%, 75% and 28% with OR of 0.80 (95% CI-.31-2.02), 0.16(95% CI-.06-.48), 0.25(95% CI-.11-.57), and 0.72(95% CI-.5-1.02), for CCP, anti-Spike mAbs, small molecule antivirals or repurposed drugs, respectively (Supplementary Table 4).

Efficacy at symptom resolution

The two effective CCP RCTs (Argentine¹⁴ and CSSC-004¹¹) did not compare time to symptom resolution, while the COV-Early¹⁸ and ConV-ert¹⁶ RCTs reported no difference in the median time of symptom resolution in the two groups¹⁶ (Table 2). The anti-Spike mAbs noted faster resolution by 1, 2, 3 or 4 days for bamlanivimab/etesevimab³, bebtelovimab¹², regdanvimab²³, and casirivimab/imdevimab²¹, respectively. The smaller bamlanivimab-only RCT did not show a difference². Of the three emergency-authorized small molecule antivirals that noted reductions in hospitalizations, molnupiravir was associated with no difference in time of symptom resolution in MOVe-OUT⁷ but improvements in both PANORAMIC²⁵ and Aurobindo²⁷ RCTs. The 3-day outpatient remdesivir RCT showed that symptoms were alleviated by day 14 nearly twice as often in the treatment arm²⁷. The nirmatrelvir/ritonavir RCT did not report on this parameter⁷. Six out of 9 RCTs in the antiviral group did not show faster symptom resolution with intervention. The three RCTs largely performed in Brazil for fluvoxamine, ivermectin³⁶ and hydroxychloroquine³³ noted no differences in symptom resolution. Metformin did not evidence faster symptom resolution despite reducing hospitalizations. 3 of the 18 RCTs reporting symptom resolution in the repurposed drug group noted faster symptom resolution.

Costs and resiliency against variants of concern

Anti-Spike mAbs and intravenous remdesivir schedules cost about 1000 to 2000 Euros per patient, respectively, while the oral drugs are much less than 1000 Euros per patient (Table 3). By comparison, the cost of CCP approximates 200 Euros per patient, and the cost for repurposed drugs is even lower. Considering the absolute risk reduction in hospitalization, the number needed to

treat to prevent a single hospitalization is often very high, as are the associated costs. With the recently patented antivirals, costs for outpatient treatment often exceeds the cost of a COVID-19 hospitalization⁵³.

mAb and mAb cocktails successively lost efficacy against Delta and Omicron, with cilgavimab (the only Omicron-active ingredient in EvusheldTM) and bebtelovimab also failing against BQ.1.1 sublineages (Figure 7). This had led the FDA to withdraw EUAs, while EMA has not restricted usage at all. Small molecule antivirals retain *in vitro* efficacy against Omicron, but concerns remain: molnupiravir showed low efficacy *in vivo*⁸ and is mutagenic for mammals *in vitro*⁵⁵, while nirmatrelvir/ritonavir has drug/drug interaction contraindications (CYP3 metabolites especially tacrolimus, anti-cholesterol, anti-migraine or many anti-depressants) and has been associated with early virological and clinical rebounds in immunocompetent patients⁵⁶. CCP from unvaccinated donors does not inhibit Omicron, but CCP from donors having any sequence of vaccination and COVID-19 or having had boosted mRNA vaccine doses universally has high Omicron-neutralizing activity.

Discussion

Outpatient RCTs are more difficult to perform by non-industrial institutions compared to drug manufacturers during an infectious disease pandemic, since switching between already constrained inpatient academic /nonindustrial personnel and outpatient spaces is challenging. By contrast, the pharmaceutical industry has well established internal resources and economical support for running outpatient trials. The relative ease of conducting inpatient RCTs may have led most initial CCP, small molecule antiviral and repurposed trials —conducted principally by academic institutions - to be based in hospitals, often in patients treated too late for antiviral treatment to be expected to work given that antiviral therapy must be given early in disease. Consistent with this, the outpatient RCT data extant confirms that most antiviral/antimicrobial therapies are more effective when given before hospital admission. The paucity of head-to-head RCTs amongst outpatient COVID-19 therapy makes clinical comparisons difficult when the RCTs were run during different times, targeting different variants and in populations with different vaccination status. Cooperation to run head-to-head intervention RCTs between different pharmaceutical companies is always more difficult. Consequently, these limitations need to be considered in our head-to-head meta-analysis assembled COVID-19 outpatient placebo controlled RCTs.

SARS-CoV-2 antibodies, whether elicited by vaccines, or provided as polyclonal (CCP) or anti-Spike mAbs, have all been demonstrated to substantially prevent progression of COVID-19 to hospitalization, as have several small molecule antivirals. Either vaccination of immunocompetent subjects and therapeutic administration of anti-Spike mAbs, generate high serum levels of neutralizing antibodies (albeit of different subclasses and at different times): dose concerns still exist for monoclonals (e.g., tixagevimab-cilgavimab⁵⁷), and the risk of treatment-emergent immune escape under selective pressure⁵⁸ has been marginally investigated. RCTs showed minimal effects of most agents on time to symptom resolution, but a more amplified effect of 50 to 80% reduction in rates of hospitalization was seen in the three major classes of outpatient treatment – CCP, anti-spike mAbs and small molecule antivirals.

Despite the heterogeneity of these 47 RCTs trials, which varied in participant age, medical risk factors, vaccination history and serological status, the assembly of these effective, yet molecularly

disparate interventions, outpatient RCTs shows the consistent importance of early outpatient treatment for patients at risk of progression ⁵⁹. Treatment within 5 days of illness onset was more effective than later treatment, as would be expected for an antiviral mechanism of action. Importantly, for CCP, increasing the dose in the Argentina RCT¹⁴ and shortening the intervention interval to within five days of illness onset produced a relative risk reduction for hospitalization close to 80%, which is comparable to (or superior) to the findings of RCTs with anti-Spike mAbs and small molecule antivirals. Overall, a reduction in mortality is suggested with these outpatient therapies, but the individual RCTs are underpowered to investigate death as an outcome.

In recent months, the clinical armamentarium was reduced to small molecule antivirals-oral molnupiravir or nirmatrelvir/ritonavir as well as three day intravenous remdesivir and CCP, since single and double ("cocktail") anti-Spike MAbs have lost effectiveness against new VOCs. Both vaccine and disease elicited antibodies are polyclonal, meaning that they include various isotypes that provide functional diversity and target numerous epitopes making variant escape much more difficult with CCP. Hence, polyclonal antibody preparations are much more resilient to the relentless evolution of variants. This is in marked contrast to mAbs, which target single epitopes of SARS-CoV-2. The exquisite anti-Spike mAb (and receptor binding domain) specificity renders them susceptible to becoming ineffective with single amino acid changes. Adding boosters to the vaccine regimen and also producing vaccine-boosted CCP provide high amounts of neutralizing antibodies which can be effective against practically any existing VOC, including Omicron⁶⁰ (so-called "heterologous immunity", likely due to the well-known phenomenon of "epitope spreading"). The vaccine-boosted CCP also has more than ten times the amount of total SARS-CoV-2 specific antibody as well as neutralizing activity compared to the pre-omicron CCP used in the effective outpatient CCP RCTs.

In addition to efficacy, other points to consider in an outpatient pandemic are tolerability, scalability and affordability. Repurposed drugs are generally well tolerated, widely available and relatively inexpensive, but have limited efficacy. On the contrary small molecule antivirals are often plagued by contraindications and side effects, which makes frail patient to rely on passive immunotherapies. Both small molecule antivirals and anti-Spike mAbs take time to develop and are unaffordable to low-and-middle income countries (LMIC). CCP is instead a tolerable, scalable, and affordable treatment.

As shown in Table 3, the market cost of anti-Spike mAbs is generally about 10 times higher than that for manufacturing CCP (at the same level of engagement), making CCP the only COVID-19 antiviral therapy affordably available in LMICs.

In light of our meta-analysis, we therefore urge the WHO to revise its guidelines in order to include CCP as an option for outpatients.

Methods

The protocol has been registered in PROSPERO, the prospective register of systematic reviews and meta-analysis of the University of York (protocol registration number CRD42022369181)

Literature search

We assembled outpatient COVID-19 RCTs with hospitalization as the primary outcome, by searching MEDLINE (through PubMed), medRxiv and bioRxiv databases for the period of March 1, 2020 to October 1, 2022, with English language as the only restriction. The Medical Subject Heading (MeSH) and search query used were: "("COVID-19" OR "SARS-CoV-2" OR "coronavirus disease 2019") AND ("treatment" OR "therapy") AND ("outpatient" OR "hospitalization")". In PubMed, the filter "Randomized Controlled Trial" was applied. We also screened the reference list of reviewed articles for additional studies not captured in our initial literature search. Interventions were classified as antiviral or supportive (repurposed) in nature. We also excluded case reports, case series, retrospective propensity matched studies, nonrandomized clinical trials, review articles, meta-analyses, low number of participants with no hospitalizations, homeopathy and zinc vitamin C study with low number of participants and original research articles reporting only aggregate data. Articles underwent a blind evaluation for inclusion by two assessors (D.S. and D.F.) and disagreements were resolved by a third senior assessor (A.C.). Figure 1 shows a PRISMA flowchart of the literature reviewing process. The following parameters were extracted from studies: baseline SARS-CoV-2 serology status time from onset of symptoms to treatment, study dates, recruiting countries, gender, age (including the fraction of participants over age 50, 60 and 65), ethnicity, risk factors for COVID-19 progression (systemic arterial hypertension, diabetes mellitus, and obesity), sample size, dosage type of control, hospitalizations and deaths in each arm, and time to symptom resolution. Study dates were used to infer predominant VOCs.

Assessment of risk of bias and GRADE assessment

A risk of bias assessment of each selected RCT was performed by COVID-19- Network Meta-Analysis (NMA)^{61, 62}. Within-trial risk of bias is assessed, using the Cochrane ROB tool for RCTs⁶³. The Cochrane 'Risk of bias' tool addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting, and other issues relating to bias. We explored clinical heterogeneity (e.g., risk factors for progression, time between onset of symptoms and treatment administration, and predominant variants of concern at the time of the interventions) and asses statistical heterogeneity using τ^2 , Cochran's Q and estimated this using the I² statistic, which examines the percentage of total variation across studies that is due to heterogeneity rather than to chance.

We used the principles of the GRADE (The Grading of Recommendations Assessment, Development and Evaluation) system to assess the quality of the body of evidence associated with specific outcomes, and constructed a 'Summary of findings' table using the software Review Manager (RevMan), Version 5.4 The Cochrane Collaboration, 2020 (available at https://training.cochrane.org/online-learning/core-software/revman/revman-5-download). The certainty of a body of evidence involves consideration of within-trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias 63. Publication bias was assessed by visual inspection of funnel plots.

Statistical methods

Descriptive analysis included time-to-treatment, geography (country) of the study, age, sex, race (white and black), ethnicity, seropositive, hospital type and medical high-risk conditions (e.g., diabetes, hypertension, and obesity or BMI > 30).

Absolute risk reduction (ARR, i.e., the arithmetic difference in hospitalization between the 2 groups) and relative risk reduction (RRR, i.e., percent reduction in risk) were used to represent the efficacy of treatment. The number needed to treat (NNT) to prevent a single hospitalization was calculated as 1/AAR.

Odds ratios (OR, the odds of hospitalization for the treatment group over the odds of hospitalization for the control group) and 95% confidence intervals (95% CI) were used to show the direction of effect and its significance in comparing treatment group and control groups. Weight, heterogeneity, between-study variance, and significance level were displayed in forest plots. Funnel plots were used to estimate the risk of publication bias.

The forest plot and the enrolment figure were used for visualization and comparison of the odds ratio among studies. The enrolment progress (duration and calendar months) of each study was shown as a Gantt plot. PRISMA flowchart was used to summarize the number of studies. The significance level was 0.05. The figures were created in Prism software, R (version 4.2.1, R Foundation) and its statistical package "meta" (version 6.0-0). All the data manipulation and the analyses were performed in Excel, Prism, MedCalc, R and REVMAN.5.

Declaration of interests

DS, DFH, AC were investigators in the CSSC-004 study; D.F. and M.F. were investigators in the TSUNAMI RCT of CCP. DJS reports AliquantumRx Founder and Board member with stock options (macrolide for malaria), Hemex Health malaria diagnostics consulting and royalties for malaria diagnostic test control standards to Alere- all outside of submitted work. AC reports being part of the scientific advisory board of SabTherapeutics and has received personal fees from Ortho Diagnostics, outside of the submitted work. All other authors report no relevant disclosures.

Contributors

DS wrote the first draft and extracted data verified by DF, and MF. DF curated Table 3 and 7 and revised the text. MC, JO, MF and DS performed statistical analyses. MC and DS performed GRADE assessment. AC, NP, MF and DH critically revised the manuscript. DS and DF directly accessed and verified the underlying data reported here. All authors read and agree with manuscript.

Data availability statement

Datasets used for this systematic review are publicly available in PubMed, medRxiv and bioRxiv.

Funding

This study was supported by the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (DS, AC, DH), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases 3R01AI152078-01S1 (DS, AC), NIH National Center for Advancing Translational Sciences U24TR001609-S3 and UL1TR003098 (DH).

Role of the funding source

The study sponsors did not contribute to the study design; the collection, analysis, and interpretation of data; manuscript preparation, and the decision to submit the paper for publication.

References

- 1. Salazar E, *et al.* Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. *Am J Pathol* **190**, 2290-2303 (2020).
- 2. Chen P, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 384, 229-237 (2021).
- 3. Dougan M, *et al.* Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. *N Engl J Med* **385**, 1382-1392 (2021).
- 4. Weinreich DM, *et al.* REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med* **384**, 238-251 (2021).
- 5. Polack FP, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383, 2603-2615 (2020).
- 6. Anderson EJ, *et al.* Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med* **383**, 2427-2438 (2020).
- 7. Hammond J, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med **386**, 1397-1408 (2022).
- 8. Jayk Bernal A, *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* **386**, 509-520 (2022).
- 9. FDA. FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19. (ed FDA) (2022).
- 10. O'Shaughnessy JA. Convalescent Plasma EUA Letter of Authorization 12282021 .) (2021).
- 11. Sullivan DJ, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med, (2022).

- 12. Dougan M, *et al.* Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. *medRxiv*, 2022.2003.2010.22272100 (2022).
- 13. Bramante CT, *et al.* Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. *N Engl J Med* **387**, 599-610 (2022).
- 14. Libster R, *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* **384**, 610-618 (2021).
- 15. Korley FK, et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. *N* Engl J Med **385**, 1951-1960 (2021).
- 16. Alemany A, *et al.* High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. *Lancet Respir Med* **10**, 278-288 (2022).
- 17. Focosi D, Casadevall A. Convalescent plasma in outpatients with COVID-19. *Lancet Respir Med* **10**, 226-228 (2022).
- 18. Millat-Martinez P, *et al.* Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. *Nature Communications* **13**, 2583 (2022).
- 19. Gharbharan A, *et al.* Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial. *Clin Microbiol Infect*, (2022).
- 20. Norton T, *et al.* REGEN-COV Antibody Combination in Outpatients With COVID-19 Phase 1/2 Results. *medRxiv*, 2021.2006.2009.21257915 (2022).
- 21. Weinreich DM, *et al.* REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med* **385**, e81 (2021).
- 22. Gupta A, *et al.* Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. *N Engl J Med*, (2021).
- 23. Streinu-Cercel A, *et al.* Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis* **9**, ofac053 (2022).

- 24. Montgomery H, *et al.* Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med* **10**, 985-996 (2022).
- 25. Butler C, *et al.* Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial. *SSRN* **ssrn.4237902**, (2022).
- 26. Tippabhotla SK, Lahiri S, Rama Raju D, Kandi C, Prasad VN. Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial. . SSRN 4042673, (2022).
- 27. Gottlieb RL, *et al.* Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *N Engl J Med* **386**, 305-315 (2022).
- 28. Feld JJ, *et al.* Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *The Lancet Respiratory Medicine* **9**, 498-510 (2021).
- 29. Jagannathan P, *et al.* Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. *Nature Communications* **12**, 1967 (2021).
- 30. Eiger BioPharmaceuticals I. Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study.). Cision Distribution (2022).
- 31. Roozbeh F, *et al.* Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. *Journal of Antimicrobial Chemotherapy* **76**, 753-757 (2020).
- 32. Bosaeed M, *et al.* Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. *Clin Microbiol Infect* **28**, 602-608 (2022).
- 33. Reis G, *et al.* Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. *JAMA Netw Open* **4**, e216468 (2021).

- 34. Reis G, *et al.* Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Health* **10**, e42-e51 (2022).
- 35. Lenze EJ, *et al.* Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA* **324**, 2292-2300 (2020).
- 36. Reis G, *et al.* Effect of Early Treatment with Ivermectin among Patients with Covid-19. *N Engl J Med*, (2022).
- 37. Rezai MS, *et al.* Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. *Front Med (Lausanne)* **9**, 919708 (2022).
- 38. Naggie S, *et al.* Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA* **328**, 1595-1603 (2022).
- 39. Mitjà O, *et al.* Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. *Clinical Infectious Diseases* **73**, e4073-e4081 (2020).
- 40. Schwartz I, *et al.* Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. **9**, E693-E702 (2021).
- 41. Skipper CP, *et al.* Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. *Ann Intern Med* **173**, 623-631 (2020).
- 42. Johnston C, *et al.* Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. *Eclinical medicine* 33, (2021).
- 43. Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D, Brechot C. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. *Eclinical medicine* **45**, 101310 (2022).
- 44. Tardif JC, *et al.* Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. *Lancet Respir Med* **9**, 924-932 (2021).

- 45. Cairns DM, *et al.* Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial. *JAMA Network Open* **5**, e2144942-e2144942 (2022).
- 46. Connors JM, *et al.* Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. *JAMA* **326**, 1703-1712 (2021).
- 47. Gonzalez-Ochoa AJ, *et al.* Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. *Thromb Haemost* **121**, 944-954 (2021).
- 48. Cools F, *et al.* Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. *Lancet Haematol* **9**, e594-e604 (2022).
- 49. Barco S, *et al.* Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol* **9**, e585-e593 (2022).
- 50. Duvignaud A, *et al.* Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). *Clin Microbiol Infect* **28**, 1010-1016 (2022).
- 51. Khorshiddoust RR, *et al.* Efficacy of a multiple-indication antiviral herbal drug (Saliravira(R)) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study. *Biomed Pharmacother* **149**, 112729 (2022).
- 52. Hinks TSC, *et al.* Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. *Lancet Respir Med* **9**, 1130-1140 (2021).
- 53. Oldenburg CE, *et al.* Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. *Jama* **326**, 490-498 (2021).
- 54. McCreary MR, Schnell PM, Rhoda DA. Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19). *Sci Rep* **12**, 10978 (2022).

- 55. Zhou S, *et al.* beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. *J Infect Dis* **224**, 415-419 (2021).
- 56. Gupta K, Strymish J, Stack G, Charness M. Rapid Relapse of Symptomatic SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. *Research Square* (2022).
- 57. Simonovich VA, *et al.* A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med* **384**, 619-629 (2020).
- 58. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. *Int J Mol Sci* **23**, 29 (2022).
- 59. Hasan Ali O, *et al.* Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. *Clinical Infectious Diseases*, (2020).
- 60. Focosi D, Franchini M, Joyner MJ, Casadevall A. Comparative analysis of antibody responses from COVID-19 convalescents receiving various vaccines reveals consistent high neutralizing activity for SARS-CoV-2 variant of concern Omicron. 2021.2012.2024.21268317 (2021).
- 61. Nguyen TV, *et al.* RCT studies on preventive measures and treatments for COVID-19. *Zenodo*, (2020).
- 62. Boutron I, *et al.* The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. *Ann Intern Med* **173**, 1015-1017 (2020).
- 63. JPT H, S G. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: *The Cochrane Collaboration*, 2011). www.handbook.cochrane.org (2011).

Table 1
Demographic and clinical characteristics of recruits in the RCTs analyzed in this review.

Study	mIT T	medi an age (rang e)	total fema le n(%)	Whit e n(%)	Blac k n(%	Hispa nic n(%)	1 or more medical high risk condito ns for COVID -19 progessi on	diabet es n(%)	hypertens ion n(%)	obesity or BMI > 30 n(%)	median duratio n sympto ms	Seropositive at baseline n(%)	Hospit al type	Endpoi nt days for hosp
CCP (5 RCTs) totals			1409	2213	266	862	2074	326		854				
or averages	2634	58	(53)	(84)	(10)	(33)	(79)	(15)	606 (33)	(38)	4.5	73 (9)		
anti-Spike mAbs (8														
RCTs) totals or			3944	6214	455	3113	6562	1067		3197				
averages	7421	47	(53)	(84)	(6)	(42)	(88)	(14)	1249 (17)	(43)	3.5	1087 (15)		
Small molecule			1811									25710 (77)		
antivirals (11 RCTs)	3314		6	2872	399	2458	22400	3150		6271		{710/8148=9%		
totals or averages	8	45.4	(55)	6 (87)	(1)	(7)	(68)	(10)	6954 (21)	(19)	4	w/o-Mol-Pan.)		
Repurposed drugs			959	1475	,				` ′					
(27 RCTs) totals or	1684		5	2	815	4212	8669	2174	4318	6615				
averages	0	48	(57)	(89)	(5)	(32)	(88)	(13)	(27)	(46)	5.1	2303 (51)		
			173	()	(-)	376	()	49	not	()		()	All	
CCP-CONV-ert16	376	56	(46)	0	0	(100)	278 (74)	(13)	reported	96 (26)	4.4	43 (11)	cause	28-30
								not		not				
CCD COVE 1 10	40.6	50	187	406			270 ((0)	report	not	reporte	5 (iqr4-	20 (0)	All	20.20
CCP-COV-Early ¹⁹	406	58	(46)	(100)	0	0	278 (68)	ed	reported	d	6)	30 (8)	cause	28-30
CCP-C3PO ¹⁵	511	54	274 (54)	237 (46)	103 (20)	156 (31)	511 (100)	142 (28)	216 (42)	302 (59)	4	not reported	All cause	15
CC1-C31 O	311	J -1	(34)	(40)	(20)	(31)	(100)	(20)	210 (42)	(33)	7	not reported	hypoxi	1.0
		77											a resp	
		(65-	100			160		36					rate	
CCP-Argentina ¹⁴	160	90+)	(62)	0	0	(100)	131 (82)	(23)	114 (71)	12 (8)	3	not reported	def	28-30

		43 (18-	675	934	163	170				444			COVI D-19	
CCP-CSSC-004 ¹¹	1181	85)	(57)	(79)	(14)	(14)	470 (40)	99 (8)	276 (23)	(38)	6	not reported	related	28-30
													COVI	
													D-19	
D 1 1		45		• • • •		400							related	
Bamlanivimab-	450	(18-	249	389	29	198	210 (60)		not	201	,		+ ED	20.20
BLAZE-1 ²	452	86)	(55)	(86)	(6)	(44)	310 (69)		reported	(44)	4	not reported	visit	28-30
Sotrovimab-	10.55	53(17	571	919	42	687	1055	233	not	665			All	20.20
COMET-ICE ²³	1057	-96)	(54)	(87)	(4)	(65)	(99.9)	(23)	reported	(63)	3	not reported	cause	28-30
Bamlanivimab/etesev		54	520	006	0.2	204		205		1.			COVI	
imab-BLAZE-1 ³	1025	(12-	538	896	83	304	002 (05)	285	not	median	4		D-19	20.20
imab-BLAZE-1°	1035	77+) 50	(52)	(87)	(8)	(29)	983 (95)	(28)	reported	34 bmi	4	not reported	related	28-30
Casirivimab/													COVI	
imdevimab-REGEN-		(iqr 39-	1407	2297	143	935	2696	412		1559			D-19	
COV Ph 3 ²¹	2696	50)	(52)	(85)	(5)	(35)	(100)	(15)	993 (37)	(58)	3	620 (23)	related	28-30
COVINS	2070	42	(32)	(03)	(3)	(33)	(100)	(13)	773 (31)	(30)	3	020 (23)	Terated	20-30
Casirivimab/		(iqr												
imdevimab-REGEN-		31-	423	681	74	403				298			All	
COV Ph 1/2 ²⁰	799	52)	(53)	(85)	(9)	(50)	483 (61)			(37)	3	304 (38)	cause	28-30
		/	(00)	(00)	(-)	(5 %)	100 (01)	not		(0,)		0 0 1 (0 0)	COVI	
Bebtelovimab-			135	187	48			report	not				D-19	
BLAZE-4 ¹²	253	34	(53)	(74)	(19)	91 (36)	0 (0)	ed	reported		3	27 (11)	related	28-30
		51												
Regdanvimab-CT-		(iqr40	166	286					not				All	
P59 ²³	307	-60)	(51)	(87)	0	27 (8)	226 (69)	29 (9)	reported	52 (16)	3	9 (3)	cause	28-30
Tixagevimab-													COVI	
cilgavimab-		46 (sd	455	559	36	468		108		388			D-19	
TACKLE ²⁴	822	15.2)	(50)	(62)	(4)	(52)	809 (90)	(12)	256 (28)	(43)	5	127 (14)	related	28-30
		43	735					228						
Molnupiravir-MOVe-		(18-	(51.3	813	75	711	1424	(15.9)	not	1056(7			All	
OUT ⁷	1408	90))	(56)	(5)	(49)	(99.4)	%	reported	3)	3	620 (23)	cause	28-30
M.1	0.500	57	1510	2.45-			4.55.0	216-		2015		0.5000 (0.0)		
Molnupiravir-	2500	(18-	1 (50)	2427	155		17759	2195	5702 (22)	3912		25333 (98) 2+	All	20.20
PANORAMIC ²⁵	0	99)	(59)	0 (94)	(0.6)		(69)	(9)%	5782 (22)	(15)%	3	doses of vaccine	cause	28-30
Molnupiravir-		36	160	1220									A 11	
Aurobindo ²⁷	1220	(18- 60)	468 (38)	1220 (100)	0	0	90 (7.3)				3	not renerted	All	28-30
Aurobilido	1220	46	(38)	(100)	U	U	90 (7.3)				3	not reported	cause COVI	28-30
Nirmatrelvir/ritonavir		(18-	1098	1607	110	1010	2085	252		744			D-19	
-EPIC-HR ⁷	2085	(18- 88)	(49)	(72)	(4.9)	(45)	(100)	(11)	739 (33)	(36)	3	27 (11)	related	28-30
-Li IC-IIK	2003	00)	(49)	(72)	(4.9)	(43)	(100)	(11)	139 (33)	(30)	J	4/(11)	rerated	20-30

		50	I						1		1	1	COVI	
Remdesivir-		(12-	269	452	42	235	562	346		310			D-19	
PINETREE ²⁷	562	77+)	(48)	(80)	(7.5)	(41)	(100)	(62)	268 (48)	(55)	5	9 (3)	related	28-30
TINETREE	302	777)	(40)	(80)	(7.5)	(41)	(100)	(02)	200 (40)	(33)	3	9(3)	COVI	26-30
Interferon Lambda-											mat		D-19	
TOGETHER ³⁰	1936										not	4		28-30
TOGETHER	1930	4.0									reported	not reported	related COVI	28-30
Interferon Lambda-		46	2.5											
	60	(iqr32	35	2.1						10	_	5/51 (10)	D-19	1.4
ILIAD ²⁸	60	-54)	(60)	31	6		9			12	5	5/51 (10)	related	14
T . C T 11		36						1.0						
Interferon Lambda-		(18-	50	33				12			5 (iqr3-	10 (11)	All	
COVID-Lambda ²⁹	120	71)	(42)	(28)		74 (63)		(10)	14 (12)		6)	49 (41)	cause	28-30
Sofosbuvir and														
daclatasvir-			29	55							not		All	
SOVODAK ³¹	55	< 50	(53)	(100)							reported	not reported	cause	28-30
		37												
Favipiravir-Avi-		(iqr32	76	231				25					All	
Mild-19 ³²	231	-44)	(33)	(100)	0	0		(11)	14 (6)	39 (17)	3	not reported	cause	28-30
		53												
		(IQR											COVI	
Lopinavir/ritonavir-		18-	255		11	428	471	92		198			D-19	
TOGETHER ³³	471	94)	(54)	14 (3)	(2)	(91)	(100)	(20)	137 (29)	(42)	6	not reported	related	90
		46												
		(iqr											COVI	
Metformin-COVID-		37-	741	1091	90				353 (27)	646			D-19	
OUT ¹³	1197	55)	(56)	(82)	(7)			26 (2)	cvd	(49)	5	690 (52fv)	related	28-30
								ì					COVI	
Fluvoxamine-			862	1486		1486	1497	243		751			D-19	
TOGETHER ³⁵	1497	< 50	(58)	(99)	5(1)	(99)	(100)	(16)	194 (13)	(50)	4	not reported	related	28-30
												•		15 (2
														noncov
]							id after
]						COVI	day 15
Fluvoxamine -STOP			109	106	38			17					D-19	to day
COVID ³⁶	152	46	(72)	(70)	(25)	5 (3)]	(11)	30 (20)	75 (49)	4	not reported	related	28
		44	(,=)	(, *)	()	- (-)		()	()	()			COVI	
Fluvoxamine-		(iqr37	358	539	51]		172 (26)	302			D-19	
COVID-OUT ¹³	592	-53)	(54)	(82)	(8)]	7(1)	cvd	(46)	5	373 (56fv)	related	28-30
	3,2	- 55,	(51)	(02)	(0)			, (1)	574	(10)		2.3 (3011)	COVI	20 30
Ivermectin-			791	1310	12	1310	1349	180		675			D-19	
TOGETHER ³⁷	1349	49	(58)	(98)	(1)	(98)	(100)	(13)	114 (8)	(50)	4	not reported	related	28-30
TOOLITEK	エンサラ	T/	(50)	(70)	(1)	(70)	(100)	(13)	117(0)	(50)		not reported	related	20-30

		46											COVI	
Ivermectin-COVID- OUT ¹³	720	(iqr37	442	662	59			12 (2)	184 (23)	383	_	440 (566)	D-19	20.20
OUT	730	-56)	(55)	(82)	(7)			13 (2)	cvd	(47)	5	449 (56fv)	related	28-30
Ivermectin Iran ³⁸	549	35 (5- 87)	294 (48)	582 (100)	0		112 (20)	42	46 (7.0)	101 (21)	,		All	not
Ivermecun Iran	349	47	(48)	(100)	U	0	112 (20)	(7.3)	46 (7.8)	(21)	3	not reported	cause	stated
Ivermectin-ACTIV-		(iqr39	932	1286	113(163							All	
6^{39}	1591	-56)	(59)	(81)	7)	(10)		184	415	648	6	753 (fv47)	cause	28-30
•	1371	53	(3)	(01)	,,	(10)		101	115	0.10		733 (1117)	caase	20 30
		(IQR											COVI	
Hydroxychloroquine-		18-	243	422		422	441	89		177			D-19	
TOGETHER ³⁴	441	81)	(55)	(96)	7(1)	(96)	(100)	(20)	210 (48)	(40)	6	not reported	related	90
		40												
** 1 11 1		(iqr												
Hydroxychloroquine-		32-	238	235	15								All	
COVID-19 PEP ⁴²	423	50)	(56)	(48)	(3)	28 (6)		15 (3)	46 (11)		2	not reported	cause	14
Hydroxychloroquine			66								7 (iqr5-		All	
-AH COVID-19 ⁴¹	148	47	(45)	51	12			29	41		8)	not reported	cause	28-30
Hydroxychloroquine-	202	42 (12	201				1.5.6.450	20 (5)			3 (iqr 2-		All	20.20
BCN PEP-CoV-2 ⁴⁰	293	sd)	(69)				156 (53)	20 (7)			4)	not reported	cause	28-30
Hydroxychloroquine-		37	121	117	26								COVI D-19	
BMG ⁴³	231	(18- 78)	131 (57)	117 (51)	(11)	71 (31)	129 (56)	17 (7)	27 (12)	98 (42)	6	not reported	related	28-30
DIVIG	231	40	(37)	(31)	(11)	/1 (31)	129 (30)	17(7)	27 (12)	90 (42)	0	not reported	COVI	20-30
Nitazoxanide-		(12-	214	233		130	238						D-19	
Romark ⁴³	379	83)	(57)	(61)	8 (2)	(34)	(63%)				2	38 (10)	related	28-30
		54	(0,7)	(0.0)	· (-)	(-1)	(0011)					(-0)		
		(iqr											COVI	
Colchicine-		47-	2421	4182	233		4488	894		2052			D-19	
COLCORONA ⁴⁴	4488	61)	(54)	(93)	(5)	<10%	(100)	(20)	1629 (36)	(46)	5.3	not reported	related	28-30
45		36	26	53							not		All	
Niclosamide ⁴⁵	67	mean	(39)	(79)	4 (6)	7 (10)			5 (8)	4 (7)	reported	not reported	cause	28-30
		54									1.0			
		(iqr	101	250	26			52		164	10		A 11	
aspirin-ACTIV-4B ⁴⁶	280	46- 59)	191 (58)	250	36	02 (20)		53 (16)	100 (22)	164 (50)	(diagnos	m ot momt 1	All	45
aspiriii-ACTIV-4B	280	59)	(38)	(76)	(11)	93 (28)		(10)	109 (33)	(30)	is)	not reported	cause	43
		(iqr				1					10			
2.5-mg apixaban-		46-	191	255	38			60		164	(diagnos		All	
ACTIV-4B ⁴⁶	271	59)	(58)	(78)	(12)	91 (28)		(18)	120 (37)	(50)	is)	not reported	cause	45
:		/	(- 0)	(. 5)	(-2)	- (=0)		()		()	10			
5-mg apixaban		54	198	251	36	1		55		164	(diagnos		All	
ACTIV-4B ⁴⁶	279	(iqr	(6	(77)	(11)	80 (24)		(17)	111 (34)	(50)	is)	not reported	cause	45

		46- 59)												
Sulodexide ⁴⁷	243	55	128 (53)	243 (100)		243 (100)		50 (21)	83 (43)		3	not reported	All cause	21
		59							, ,			•		
		(iqr51	96	129				50/152	114/152	109			All	
Enoxaparin-ETHIC ⁴⁹	219	-66)	(44)	(59)	5 (2)	12 (5)		(33)	(75)	(49)	5	not reported	cause	21
		56												
		(iqr53	217	446									All	
Enoxaparin-OVID ⁵⁰	572	-62)	(38)	(78)	3 (1)			38 (7)	115 (20)		3 (dx)	not reported	cause	28-30
		63												
Inhaled ciclesonide-		(50-	111	217									All	
COVERAGE ⁵⁰	217	86)	(51)	(100)	0	0	157 (72)	33(16)	89 (41)	52 (24)	4	not reported	cause	28-30
		50												
		(24-	59	143							not		All	
Saliravira ⁵¹	143	80)	(41)	(100)					33 (23)		reported	not reported	cause	23
Azithromycin-			143	201	11								All	
Atomic2 ⁵²	292	46	(49)	(68)	(4)		70 (24)	25 (9)	52 (18)		6	not reported	cause	28-30
Azithromycin-			130	169				24					All	
ACTION ⁵³	197	43	(66)	(86)	9 (5)	59 (30)		(12)	26 (13)		6	not reported	cause	21
		55												
		(45-	62	93				10					All	
Resveratrol ⁵⁴	100	84)	(59)	(89)	4 (4)	2(2)	32 (30)	(10)		50 (50)	5	not reported	cause	21

Table 2
Hospital rates, risk reductions, NNT, numbers and symptom resolution

Study	Contro l hospita lization s %	hospitali zations % in interven tion arm	ARR percent (95% CI)	RRR percent (95% CI)	NNT to prevent 1 hospitali zation	Hospitaliz ation (n) in control arm	total pts in control arm (n)	Hospitaliz ation (n) in interventio n arm	Total pts (n) in interven tion arm	Symptom resolution: median duration- Intervention to control in days
CCP (5 RCT) %			3.2 (0.9,	26.8 (8.1,						
or totals	12.0	8.8	5.6)	41.7)	31	158	1315	116	1319	
anti-Spike mAbs (8			3.7 (2.8,	67.2 (57.1,						
RCT) % or totals	5.5	1.8	4.6)	74.9)	27	190	3443	72	3978	
Small molecule antiviral (11										
RCTs) total or			0.7 (0.4,	34.5 (22.2,						
average	1.9	1.3	0.9)	44.9)	149	322	16606	210	16542	
Small molecule antiviral (10 RCTs										
-w/o Mol-Pan.)			2.8 (2.0,	51.5 (39.2,						
total or average	5.5	2.7	3.7)	61.3)	35	226	4122	107	4026	
Repurposed drugs (20 RCTs) total or			1.4 (0.7,	21.9 (11.7,						
average	6.5	5.1	2.1)	30.9)	70	541	8316	433	8524	
All (47 RCTs) total			1.3 (1.1,	32.9 (26.8,						
or average	4.1	2.7	1.6)	38.5)	74	1211	29680	831	30363	
16			-0.5 (-	-4.8 (-83.9,	100		100		100	NO difference 12 d
CCP-CONV-ert ¹⁶	11.2	11.7	7.0, 5.9)	40.3)	-188	21	188	22	188	vs 12 d
CCP-COV-Early ¹⁹	9.3	5.9	3.4 (-1.8, 8.5)	36.2 (-27.9, 68.2)	29	19	204	12	202	NO difference 13 d vs 12 d
CCI-COV-Larry	7.3	3.7	1.8 (-5.3,	8.2 (-28.3,	43	17	204	12	202	v5 12 U
CCP-C3PO ¹⁵	22.0	20.2	8.9)	8.2 (-28.3, 34.4)	55	56	254	52	257	NO difference

		1	1			1	1		
			` '						
31.3	16.3		· · · · · · · · · · · · · · · · · · ·	7	25	80	13	80	Not reported
			, ,						
6.3	2.9		<u> </u>	29	37	589	17	592	Not reported
		, .	, ,						
8.3	31.3	36.5)	91.4)	4	25	80	3	36	Not reported
1.0	0.7	7.7 (3.7,	79.9 (48.4,						
1.9	9.7	11.7)	92.2)	13	25	259	5	257	Not reported
		4.7 (0.5,	74.3 (24.7,						NO difference 11 d
6.3	1.6	8.9)	91.2)	21	9	143	5	309	to 11 d
		4.5 (2.4,	80.0 (52.3,						
5.7	1.1	6.7)	91.6)	22	30	529	6	528	Not reported
		4.8 (2.3,	69.5 (40.8,						YES- 8d vs 9d
7.0	2.1	7.4)	84.3)	21	36	517	11	518	p=0.007
		3.3 (2.0,	71.3 (51.7,						YES- 10 d vs 14
4.6	1.3	4.6)	82.9)	30	62	1341	18	1355	p=0.0001
		1.3 (-0.4,	70.1 (-24.4,						
1.9	0.6	3.1)	92.8)	76	5	266	3	533	Not reported
		-0.4 (-	-2.4 (-615.7,						YES- 6d to 8d
1.6	1.6	3.1, 3.0)	85.4)	-2667	2	128	2	125	p=0.003
		4.2 (-1.9,	48.8 (-25.2,						YES 6 d vs 9 d
8.7	4.4	10.3)	79.0)	23	9	104	9	203	p=0.01
		4.5 (1.1,	50.4 (14.3,						
8.9	4.4	7.9)	71.3)	22	37	415	18	407	Not reported
		3.0 (0.1,	30.4 (0.8,						•
9.7	6.8	5.8)	51.2)	34	68	699	48	709	NO difference
		-0.1 (-	<u> </u>						
0.8	0.8	0.3, 0.2)	18.9)	-1853	96	12484	103	12516	YES 9 d vs 15 d
			,						Yes 10 d vs 14 d
0.0	0.0	NC	NC	0	0	610	0	610	p<0.001
	5.7 7.0 4.6 1.9 1.6 8.7 8.9 9.7 0.8	6.3 2.9 8.3 31.3 1.9 9.7 6.3 1.6 5.7 1.1 7.0 2.1 4.6 1.3 1.9 0.6 1.6 1.6 8.7 4.4 9.7 6.8 0.8 0.8	6.3 2.9 3.4 (1.0, 5.8) 8.3 31.3 36.5) 1.9 9.7 7.7 (3.7, 11.7) 4.7 (0.5, 8.9) 4.5 (2.4, 6.7) 5.7 1.1 6.7) 4.8 (2.3, 7.4) 7.4) 3.3 (2.0, 4.6) 1.3 (-0.4, 3.1) 1.9 0.6 3.1) -0.4 (-1.6 3.1, 3.0) 4.2 (-1.9, 10.3) 4.5 (1.1, 7.9) 8.7 4.4 7.9) 3.0 (0.1, 5.8) 5.8) -0.1 (-0.8) 0.8 0.3, 0.2)	31.3 16.3 28.0) 71.3) 31.3 16.3 28.0) 71.3) 3.4 (1.0, 54.3 (19.7, 74.0) 54.8) 74.0) 22.9 (9.3, 73.3 (17.4, 91.4) 73.3 (17.4, 91.4) 1.9 9.7 7.7 (3.7, 79.9 (48.4, 11.7) 1.9 9.7 4.7 (0.5, 74.3 (24.7, 91.2) 6.3 1.6 8.9) 91.2) 4.5 (2.4, 80.0 (52.3, 91.2) 91.6) 4.8 (2.3, 69.5 (40.8, 84.3) 7.0 2.1 7.4) 84.3) 3.3 (2.0, 71.3 (51.7, 46.6) 82.9) 1.3 (-0.4, 70.1 (-24.4, 92.8) 92.8) -0.4 (- 2.4 (-615.7, 92.4) 92.8) -0.4 (- 3.1, 3.0) 85.4) 4.2 (-1.9, 48.8 (-25.2, 79.0) 8.7 4.4 10.3) 79.0) 4.5 (1.1, 50.4 (14.3, 79.0) 71.3) 3.0 (0.1, 30.4 (0.8, 5.8) 51.2) -0.1 (- 7.0 (-41.2, 0.3, 0.2) 18.9)	31.3 16.3 28.0) 71.3) 7 6.3 2.9 5.8) 74.0) 29 22.9 (9.3, 73.3 (17.4, 3) 36.5) 91.4) 4 1.9 9.7 7.7 (3.7, 79.9 (48.4, 11.7) 92.2) 13 4.7 (0.5, 74.3 (24.7, 91.2) 91.2) 21 4.5 (2.4, 80.0 (52.3, 91.2) 21 22 5.7 1.1 6.7) 91.6) 22 4.8 (2.3, 69.5 (40.8, 91.2) 21 3.3 (2.0, 71.3 (51.7, 91.6) 22 4.6 1.3 4.6) 82.9) 30 1.3 (-0.4, 70.1 (-24.4, 3) 3.1 92.8) 76 -0.4 (- 2.4 (-615.7, 1.3 (51.	31.3 16.3 28.0) 71.3) 7 25 3.4 (1.0, 54.3 (19.7, 29 37 6.3 2.9 5.8) 74.0) 29 37 8.3 31.3 36.5) 91.4) 4 25 1.9 9.7 7.7 (3.7, 79.9 (48.4, 11.7) 92.2) 13 25 4.7 (0.5, 74.3 (24.7, 11.7) 92.2) 21 9 4.5 (2.4, 80.0 (52.3, 91.2) 21 9 5.7 1.1 6.7) 91.6) 22 30 4.8 (2.3, 69.5 (40.8, 7.4) 84.3) 21 36 7.0 2.1 7.4) 84.3) 21 36 1.3 (-0.4, 70.1 (-24.4, 82.9) 30 62 1.9 0.6 3.1) 92.8) 76 5 -0.4 (2.4 (-615.7, 13.1, 3.0) 85.4) -2667 2 4.2 (-1.9, 48.8 (-25.2, 13.3) 9 4.5 (1.1, 50.4 (14.3, 79.0) 23 9 4.5 (1.1, 50.4 (0.8, 58.) 5.8) 51.2) 34 68 9.7 6.8 5.8) 51.2) 34	31.3 16.3 28.0) 71.3) 7 25 80 3.4 (1.0, 54.3 (19.7, 29 37 589 6.3 2.9 5.8) 74.0) 29 37 589 8.3 31.3 36.5) 91.4) 4 25 80 1.9 9.7 7.7 (3.7, 79.9) (48.4, 11.7) 25 259 4.7 (0.5, 74.3 (24.7, 92.2) 13 25 259 4.3 (24.4, 80.0 (52.3, 91.2) 91.2) 21 9 143 5.7 1.1 6.7) 91.6) 22 30 529 7.0 2.1 7.4) 84.3) 21 36 517 3.3 (2.0, 71.3 (51.7, 46.6) 82.9) 30 62 1341 1.9 0.6 3.1) 92.8) 76 5 266 -0.4 (2.4 (-615.7, 31.3) 3.1, 30.0) 85.4) -2667 2 128 8.7 4.4 10.3) 79.0) 23 9 104 8.9 4.4 7.9) 71.3) 22 37 415 8.9 4.4 7.9) 71.3) 22 37 415 8.9 4.4 7.9) 71.3) <td>31.3 16.3 28.0) 71.3) 7 25 80 13 6.3 2.9 5.8) 74.0) 29 37 589 17 8.3 31.3 36.5) 91.4) 4 25 80 3 1.9 9.7 7.7 (3.7, 79.9) (48.4, 11.7) 92.2) 13 25 259 5 4.7 (0.5, 74.3 (24.7, 92.2) 13 25 259 5 4.7 (0.5, 74.3 (24.7, 92.2) 91.2) 21 9 143 5 5.7 1.1 6.7) 91.6) 22 30 529 6 4.8 (2.3, 69.5 (40.8, 84.3) 21 36 517 11 3.3 (2.0, 71.3 (51.7, 4.6) 82.9) 30 62 1341 18 1.9 0.6 3.1, 3.0 82.9) 30 62 1341 18 1.6 1.6 3.1, 3.0 85.4) -2667 2 128 2 8.7 4.4 10.3) 79.0) 23 9 104 9 8.9 4.4 7.9) 71.3) 22 37 415 18 8.9 4.4 7.9) 71.3) 22 37 415<</td> <td> 16.3</td>	31.3 16.3 28.0) 71.3) 7 25 80 13 6.3 2.9 5.8) 74.0) 29 37 589 17 8.3 31.3 36.5) 91.4) 4 25 80 3 1.9 9.7 7.7 (3.7, 79.9) (48.4, 11.7) 92.2) 13 25 259 5 4.7 (0.5, 74.3 (24.7, 92.2) 13 25 259 5 4.7 (0.5, 74.3 (24.7, 92.2) 91.2) 21 9 143 5 5.7 1.1 6.7) 91.6) 22 30 529 6 4.8 (2.3, 69.5 (40.8, 84.3) 21 36 517 11 3.3 (2.0, 71.3 (51.7, 4.6) 82.9) 30 62 1341 18 1.9 0.6 3.1, 3.0 82.9) 30 62 1341 18 1.6 1.6 3.1, 3.0 85.4) -2667 2 128 2 8.7 4.4 10.3) 79.0) 23 9 104 9 8.9 4.4 7.9) 71.3) 22 37 415 18 8.9 4.4 7.9) 71.3) 22 37 415<	16.3

Nirmatrelvir/ritonav			5.5 (4.0,	87.8 (74.7,						
ir-EPIC-HR ⁷	6.3	0.8	7.1)	94.1)	18	66	1046	8	1039	Not reported
										YES- Alleviation of
										symptoms by day 14
Remdesivir-			4.6 (1.8,	86.5 (41.4,						(rate ratio, 1.92; 95%
PINETREE ²⁷	5.3	0.7	7.4)	96.9)	22	15	283	2	279	CI, 1.26 to 2.94)
Interferon Lambda-			2.9 (1.1,	51.2 (22.5,						
TOGETHER ³⁰	5.6	2.7	4.6)	69.2)	35	57	1020	25	916	Not reported
Interferon Lambda-			0 (-9.1,	0 (-1426,		1				NT 1:00
ILIAD ²⁸	3.3	3.3	9.1)	93.4)		1	30	1	30	No difference
Interferon Lambda-			0 (-6.4,	0 (-586.9,						NO difference 20 d
COVID-Lambda ²⁹	3.3	3.3	6.4)	85.4)		2	60	2	60	vs 20 d
Sofosbuvir and			10.6 (-							
daclatasvir-			4.2,	74.1 (-117,						NO difference in 7 d
SOVODAK ³¹	14.3	3.7	25.4)	96.9)	9	4	28	1	27	symptoms
Favipavir-Avi-			-3.7 (-	-219 (-1447,						NO difference 7d vs
Mild-19 ³²	1.7	5.4	8.4, 1.1)	34.3)	-27	2	119	6	112	7d
Lopinavir/ritonavir-			-0.9 (-	-18.4 (-155.4,						NO difference by
TOGETHER ³³	4.8	5.7	4.9, 3.1)	45.1)	-112	11	227	14	244	Cox proportional HR
Metformin-COVID-			1.8 (0.1,	57.5 (3.8,						
OUT ¹³	3.2	1.3	3.5)	81.3)	55	19	601	8	596	NO difference
Fluvoxamine-			2.7 (-0.5,	21.1 (-4.8,						NO difference- 40%
TOGETHER ³⁵	12.8	10.1	5.9)	40.6)	37	97	756	75	741	resolved by day 14
										YES (100% vs
Fluvoxamine-STOP			8.3 (1.9,							91.7% resolved on
COVID ³⁶	8.3	0.0	14.7)	1(1, 1)	12	6	72	0	80	day 7) p=0.009
										No difference (14
Fluvoxamine-			-0.3 (-	-17.6 (-281,						symptoms on 4 pt
COVID-OUT ¹³	1.7	2.0	2.5, 1.9)	63.7)	-333	5	293	6	299	scale over 14 days)
Ivermectin-			1.8 (-2.1,	11.1 (-14.7,						NO difference- 40%
TOGETHER ³⁷	15.9	14.1	5.6)	31.1)	57	107	675	95	674	resolved by day 14
										No difference (14
Ivermectin-COVID-			0.3 (-1.3,	23.9 (-181,						symptoms on 4 pt
OUT ¹³	1.4	1.1	1.9)	79.4)	299	5	356	4	374	scale over 14 days

			-2.1 (-	-42.3 (-178,						
Ivermectin Iran ³⁸	5.0	7.1	6.1, 1.9)	27.2)	-47	14	281	19	268	NO difference
Ivermectin-ACTIV-		,,,,	-0.1 (-	-5.3 (-158,	.,					No difference (12d
6 ³⁹	1.2	1.2	1.1, 1.0)	57.0)	-1634	9	774	10	817	vs 13 d)
Hydroxychloroquin			1.1 (-2.7,	22.9 (-88.1,						NO difference by
e-TOGETHER ³⁴	4.8	3.7	4.9)	68.4)	90	11	227	8	214	Cox proportional HR
				·						NO Difference in
Hydroxychloroquin			2.4 (-1.1,	50.2 (-43.1,						symptom severity
e-COVID-19 PEP ⁴²	4.7	2.4	5.9)	82.7)	42	10	211	5	212	score over 14 days
Hydroxychloroquin			-3.6 (-							NO difference 14 d
e -AH COVID-19 ⁴¹	0.0	3.6	7.1, -0.1)	NA	-28	0	37	4	111	vs 12 d
Hydroxychloroquin										
e-BCN PEP-CoV-			1.1 (-4.5,	16.0 (-103,						NO difference 10 d
2^{40}	7.0	5.9	6.7)	65.2)	89	11	157	8	136	vs 12 d
Hydroxychloroquin			1.4 (-4.0,	29.9 (-154,						NO difference 11 d
e-BMG ⁴³	4.8	3.4	6.9)	80.6)	69	4	83	5	148	vs 12 d
										Yes mild illness (13
										d vs 18 d, p=0.01),
Nitazoxanide-			2.0 (-0.4,	78.8 (-79.7,						NO difference for
Romark ⁴³	2.6	0.5	4.5)	97.5)	49	5	195	1	184	moderate illness
Colchicine-			1.2 (-0.1,	20.0 (-2.8,						
COLCORONA ⁴⁴	5.8	4.7	2.5)	37.7)	86	131	2253	104	2235	Not reported
			2.9 (-2.7,							NO difference 12 d
Niclosamide ⁴⁵	2.9	0.0	8.6)	1 (1, 1)	34	1	34	0	33	vs 15 d
Aspirin-ACTIV-			0.04 (-	5.6 (-1395,						
$4B^{46}$	0.7	0.7	1.9, 2.0)	94)	2448	1	136	1	144	Not reported
2.5-mg apixaban-			-0.01 (-	-0.7 (-1494,						
ACTIV-4B ⁴⁶	0.7	0.7	2.0, 2.0)	93.6)	-18360	1	136	1	135	Not reported
5-mg apixaban			-0.7 (-	-90.2 (-1974,						
ACTIV-4B ⁴⁶	0.7	1.4	3.1, 1.7)	82.6)	-151	1	136	2	143	Not reported
			11.7							
			(1.1,	39.7 (3.5,						
Sulodexide ⁴⁷	29.4	17.7	22.3)	62.3)	9	35	119	22	124	Not reported
Enoxaparin-			-0.9 (-	-8.6 (-131,						
ETHIC ⁴⁹	10.5	11.4	9.2, 7.4)	49.0)	-111	12	114	12	105	Not reported

			-0.1 (-	-1.7 (-166,						
Enoxaparin-OVID ⁵⁰	3.4	3.4	3.3, 3.2)	61.2)	-1740	8	238	8	234	Not reported
Inhaled ciclesonide-			-1.5 (-	-13.5 (-134,						NO difference 13 d
COVERAGE ⁵⁰	11.2	12.7	10.1, 7.1)	45.0)	-66	12	107	14	110	vs 12 d
			28.6							
			(16.7,							YES 9d vs 14 d
Saliravira ⁵¹	28.6	0.0	40.4)	1 (1, 1)	4	16	56	0	87	p<0.05
Azithromycin-			1.2 (-5.9,	10.5 (-72.3,						
Atomic2 ⁵²	11.6	10.3	8.4)	53.6)	82	17	147	15	145	Not reported
Azithromycin-			-4.0 (-							No difference
ACTION ⁵³	0.0	4.0	7.4, -0.6)	NA	-25	0	72	5	125	resolution day 14
			4.0 (-3.6,	66.7 (-210,						
Resveratrol ⁵⁴	6.0	2.0	11.6)	96.4)	25	3	50	1	50	Not reported

Table 3
Summary of historical efficacy of different therapeutics against SARS-CoV-2 VOCs. White = drug not available at that time; green = effective; orange = partially effective; red= not effective. Restriction reported refer to initial restrictions by FDA. NNT: number needed to treat.

	approximate cost per patient	average NNT (sourced from Table 2)	cost to prevent a single hospitalization (€)	efficacy against VOC Alpha	efficacy against VOC Delta	efficacy against VOC BA.1	efficacy against VOC BA.2	efficacy against BA.4/5	efficacy against BQ.1.1
bamlanivimab+etesesevimab	2000	21	42,000		restricted 04/2021				
casirivimab+imdevimab	2000	30	60,000			restricted 01/2022			
sotrovimab	1000	22	22,000				restricted 03/2022		
tixagevimab+cilgavimab	1000	22	22,000						restricted 10/22
regdanvimab	300	23	6,900						
bebtelovimab	2000	Not calculated (low-risk pts)	Not calculated (low-risk pts)						
nirmatrelvir	635 (5 days)	18	11,435						
molnupiravir	635 (5 days))	34	21,590						
remdesivir	1600 (3 days)	22 (MOVE- Out)	35,200						
CCP Vax-CCP	200 (600-ml)	31	6,200						

Figure 1
PRISMA flowchart for randomized controlled trials (RCT) selection in this systematic review.




Figure 2

Duration and calendar months of the RCT in context of dominant variant(s) of concern and seropositivity rates. Study start and end for enrollments are charted with approximate time periods for variants of concern.

perious for var	ıaı	113	01 (7011	CCI	11.					i																
																											Baseline
																											Antibody
		MAR-										JAN-												JAN-			Positive
Study	mon		A DD	MAY	ILINI		AUG	CED	ОСТ	NOV	DEC	21	FEB	MAR	ADD	MAY	ILINI	JUL	AUG	CED	ост	NOV	DEC	21	CCD	MAR	
Study	9	120	APR	IVIAT	JUN	JUL	AUG	SEP	UCI	NOV	2	3	4	5	6 6	IVIAT	8 8	9	AUG	SEP	UCI	NUV	DEC	21	FED	IVIAR	
CCP-CONV-ert										2	3	4	5		7	8	9	10									11%
CCP-COV-early	10								1				7	6	/	8	9	10							-		8%
CCP-C3PO	7						1	2	3	4	5	6	7														NR
CCP-Argentina	5				1	2	3	4	5																		NR
CCP-CSSC-004	16				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16							NR
Bamlanivimab-BLAZE-1	3							1	2	3																	NR
Sotrovimab-COMET-ICE	6							1	2	3	4	5	6														NR
Bamlanivimab/etesevimab-	3							1	2	3																	NR
Casirivimab/imdevimab-REGEN-	4								1	2	3	4															23%
Casirivimab/imdevimab-REGEN-	3					1	2	3																			38%
Bebtelovimab-BLAZE-4	3															1	2	3									11%
Regdanvimab-CT-P59	2								1	2																	3%
Tixagevimab-cilgavimab-TACKLE	6												1	2	3	4	5	6									14%
Molnupiravir-MOVe-OUT	6	_	L T	<u> </u>	┗ ¯	L T	_	┗ ¯	┖ -	┗ ¯	_	┖ -	L	┗ ¯	┗ ¯	1	2	3	4	5	6	_	_	_	L	L	23%
Molnupiravir-PANORAMIC	5										1	2	3	4	5												98%
Molnupiravir-Aurobindo	2																	1	2								NR
Nirmatrelvir/ritonavir-EPIC-HR	6																	1	2	3	4	5	6				11%
Remdesivir-PINETREE	8							1	2	3	4	5	6	7	8												3%
Interferon Lambda-TOGETHER	9																	1	2	3	4	5	6	7	8	9	NR
Interferon Lambda- ILIAD	4			1	2	3	4											-		3	-	,	U	,	0		10%
Interferon Lambda-COVID-	-			1		3	4																				10/6
	2				2																						41%
Lambda	2		-	1	2																						
Sofosbuvir & daclatasvir-SOV			1					-	_		_	_	_	_	-										-		NR
Favipiravir-Avi-Mild-19	12						1	2	3	4	5	6	7	8	9	10	11	12									NR
Lopinavir/ritonavir-TOGETHER	4				1	2	3	4																			NR
Metformin-COVID-OUT	13											1	2	3	4	5	6	7	8	9	10	11	12	13			52% FV
Fluvoxamine-TOGETHER	8											1	2	3	4	5	6	7	8								NR
Fluvoxamine -STOP COVID	4		1	2	3	4																					NR
Fluvoxamine-COVID-OUT	13											1	2	3	4	5	6	7	8	9	10	11	12	13			56% FV
Ivermectin-TOGETHER	5														1	2	3	4	5								NR
Ivermectin-COVID-OUT	13											1	2	3	4	5	6	7	8	9	10	11	12	13			56% FV
Ivermectin Iran	7												1	2	3	4	5	6	7								NR
Ivermectin-ACTIV-6	7																	1	2	3	4	5	6	7			47%
Hydroxychloroquine-TOGETHER	4				1	2	3	4																			NR
Hydroxychloroquine-COVID-19							-																		1		
PEP	2	1	2																								NR
		1	2																								INK
Hydroxychloroquine -AH COVID-																											
19	1			1	-																				-		NR
Hydroxychloroquine-BCN PEP-																											
CoV-2	2		1	2																							NR
Hydroxychloroquine-BMG	3		1	2	3																						NR
Nitazoxanide-Romark	5						1	2	3	4	5																10%
Colchicine-COLCORONA	9	1	2	3	4	5	6	7	8	9																	NR
Niclosamide	7								1	2	3	4	5	6	7												NR
Aspirin-ACTIV-4B	10							1	2	3	4	5	6	7	8	9	10										NR
2.5-mg apixaban-ACTIV-4B	10							1	2	3	4	5	6	7	8	9	10										NR
5-mg apixaban ACTIV-4B	10							1	2	3	4	5	6	7	8	9	10										NR
Sulodexide	2				1	2																					NR
Enoxaparin-ETHIC	12			l		_				1	2	3	4	5	6	7	8	9	10	11	12						NR
Enoxaparin-OVID	17						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				NR
Inhaled ciclesonide-COVERAGE	7								,	7	,	1	2	3	4	5	6	7	13	17	13	10	1/				NR
	3			+					+		1	2	3	3	4	3	0	/									NR NR
Saliravira				-	_	~	-		-	_			3				-					-	-	-	1	1	
Azithromycin-Atomic2	8	<u> </u>		-	1	2	3	4	5	6	7	8	_														NR
Azithromycin-ACTION	9	<u> </u>		<u> </u>	1	2	3	4	5	6	7	8	9												1	<u> </u>	NR
Resveratrol	3							1	2	3																	NR
614G		614G	614G	614G	614G	614G	614G	614G	614G	614G	614G			614G	614G												
Alpha												α	α	α	α	α	α										
Beta													β	β	β	β											
Delta	1	1	1		1	1		1	1	1		1	1	1	1			δ	δ	δ	δ	δ	δ	δ		1	1
Omicron	_									_			_									-	0	-		_	

Figure 3
Comparison of mean interval from symptom onset to enrollment/intervention as well as per protocol interval inclusion limit for all participants.




Figure 4

Percent hospitalizations in control groups sorted by therapy type and descending control hospitalization rates.






Figure 5


Odds ratio for hospitalizations with diverse therapeutic interventions, grouped according to mechanism of action (CCP, anti-Spike mAbs, small molecule antivirals and repurposed drugs). CCP- Fixed effect model



Anti-Spike mAbs- Fixed effect model




Small Molecule antivirals- Random effect model



Repurposed Drugs-Fixed effect model

Study	Interve Events		Co Events	ontrol Total	Odds Ratio	OR	95%-CI	Weight
Metformin-COVID-OUT	8	596	19	601		0.42	[0.18: 0.96]	3.7%
Fluvoxamine-TOGETHER	75	741	97	756		0.77	[0.56; 1.05]	17.2%
Fluvoxamine -STOP COVID	0	80	6	72 ↔	· il	0.06	[0.00; 1.15]	1.4%
Fluvoxamine-COVID-OUT	6	299	5	293		1.18	[0.36: 3.91]	1.0%
Ivermectin-TOGETHER	95	674	107	675	- in -	0.87	[0.65; 1.18]	18.3%
Ivermectin-COVID-OUT	4	374	5	356		0.76	[0.20; 2.85]	1.0%
Ivermectin Iran	19	268	14	281	 •	1.46	[0.71; 2.96]	2.5%
Ivermectin-ACTIV-6	10	817	9	774		1.05	[0.43; 2.61]	1.8%
Hydroxychloroquine-TOGETHER	8	214	11	227		0.76	[0.30; 1.93]	2.1%
Hydroxychloroquine-COVID-19 PEP	5	212	10	211	- + ! -	0.49	[0.16; 1.45]	2.0%
Hydroxychloroquine -AH COVID-19	4	111	0	37	- -	→ 3.14	[0.17; 59.70]	0.1%
Hydroxychloroquine-BCN PEP-CoV-2	8	136	11	157		0.83	[0.32; 2.13]	1.9%
Hydroxychloroquine-BMG	5	148	4	83		0.69	[0.18; 2.65]	1.0%
Nitazoxanide-Romark	1	184	5	195 ←	- 	0.21	[0.02; 1.79]	1.0%
Colchicine-COLCORONA	104		131	2253	*	0.79	[0.61; 1.03]	24.8%
Niclosamide	0	33	1	34 ←		- 0.33	[0.01; 8.48]	0.3%
Aspirin-ACTIV-4B	1	144	1	136 -	<u> </u>	0.94	[0.06; 15.24]	0.2%
2.5-mg apixaban-ACTIV-4B	1	135	1	136		1.01	[0.06; 16.27]	0.2%
5-mg apixaban ACTIV-4B	2	143	1	136	- !! -	→ 1.91	[0.17; 21.36]	0.2%
Sulodexide	22	124	35	119		0.52	[0.28; 0.95]	5.9%
Enoxaparin-ETHIC	12	105	12	114	- 	1.10	[0.47; 2.56]	2.0%
Enoxaparin-OVID	8	234	8	238		1.02	[0.38; 2.76]	1.5%
Inhaled ciclesonide-COVERAGE	14	110	12	107	- •	1.15	[0.51; 2.63]	2.1%
Saliravira	0	87	16	56 ←		0.01	[0.00; 0.24]	4.0%
Azithromycin-Atomic2	15	145	17	147		0.88	[0.42; 1.84]	3.0%
Azithromycin-ACTION	5	125	0	72			[0.36; 121.45]	0.1%
Resveratrol	1	50	3	50 ←	,	0.32	[0.03; 3.18]	0.6%
Common effect model		8524	541	8316	÷	0.77	[0.68; 0.88]	100.0%
Heterogeneity: $I^2 = 4\%$, $\tau^2 < 0.0001$, $p = 0.40$)					1 1		
Test for overall effect: $z = -3.82$ ($p < 0.01$)				0.0	5 0.5 1 2	10 20		

Figure 6
Odds ratio for hospitalization in RCT subgroups treated within 5 days since onset of symptoms




It is made available under a CC-BY-ND 4.0 International license.

Figure 7

Venn diagram of anti-Spike mAb efficacy against Omicron sublineages. *In vitro* activity of currently approved anti-Spike mAbs against Omicron sublineages circulating as of October 2022. Specific Omicron Spike amino acid mutations causing baseline ≥ 4-fold-reduction in neutralization against mAbs are reported. Mutations for which the majority of studies are concordant are reported: the different fold-reductions for each mAb are identified across concordant studies as color coded numbers defining the mean median values of specific reduction in each study. Sourced from https://covdb.stanford.edu/page/susceptibility-data (accessed on November 7, 2022

* L452R occurs in all BA.4/BA.5 lineages, but only in several BA.2. sublineages.

! R346X and K444X occur in a growing number of BA.2 and BA.4/5 sublineages as a result of convergent evolution.



Supplementary Table 1 GRADE evaluation by RCT.

Patient or population: COVID-19 outpatients
Settings: Ambulatory patients with COVID-19
Intervention: COVID-19 convalescent plasma, anti-Spike mAbs, small molecule antivirals and repurposed drugs

Comparison: standard of care, placebo

Study	Assumed risk-controls Illustrative comparativ	Correspondin g risk-Intervention Illustrative comparative	Effect size: OR (95% CI)	No of Participa nts (studies)	Quality of the evidence (GRADE)	Comments
	e risks* (95% CI)	risks* (95% CI)				
CCP						
CCP- CONV- ert ¹⁶	111 per 1000	116 per 1000 (from 61 to 219)	1.05 (0.55/1.9 8)	376 (1)	⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	CCP does not reduce hospitalization compared to placebo
CCP- COV- Early ¹⁹	93 per 1000	57.6 per 1000 (from 26.9 to 120.9)	0.62 (0.29/1.3 0)	406 (1)	⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	It is unclear if CCP reduces hospitalization compared to placebo
CCP- C3PO ¹⁵	220 per 1000	198 per 1000 (from 127 to 301)	0.9 (0.58/1.3 7)	511 (1)	⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	It is unclear if CCP reduces hospitalization compared to placebo
CCP- Argentina	312 per 1000	133 per 1000 (from 62 to 180)	0.43 (0.20/0.9 1)	160 (1)	⊕⊕⊕⊖ moderate (downgraded for imprecision due to low number of participants)	CCP reduces rate of hospitalization compared to placebo
CCP- CSSC- 004 ¹¹	62.8 per 1000	27.6 per 1000 (from 15.7 to 49.6)	0.44 (0.25/0.7 9)	1181 (1)	⊕⊕⊕ high (there are no concerns in any of the	CCP reduces rate of hospitalization compared to placebo

					GRADE factors)	
CCP- mITT all cause hospitaliz ation: cumulativ e results	120 po 1000	er 82 per 1000 (from 63 to 108)	0.69(0.53 /0.90)	2634 participa nts (5 RCTs)	⊕⊕⊕ high (there are no concerns in any of the GRADE factors)	CCP reduces significantly need of hospitalization compared to placebo. Most information is from results at low risk of bias or with some concerns, but unlikely to lower confidence in the estimate of effect.
Anti-Spike n	nAbs				I	
Bamlanivi mab ²	62.9 po 1000	er 15 per 1000 (from 5 to 46.5)	0.24 (0.08/0.7 4)	919 (1 RCT)	⊕⊕⊕⊝ moderate(downgraded for imprecision)	Bamlanivimab reduces need of hospitalization compared to placebo
Sotrovima b- COMET- ICE ²³	56.7 po 1000	10.7 per 1000 (from 4.5 to 26)	0.19 (0.08/0.4 6)	1061 (1 RCT)	⊕⊕⊕⊖ moderate (downgraded for ROB)	Sotrovimab reduces need of hospitalization compared to placebo
Bamlanivi mab/etese vimab ³	69.3 po 1000	20 per 1000 (from 10.3 to 40.1)	0.29 (0.15/0.5 8)	1035 (1 RCT)	⊕⊕⊖⊝ low(downgraded for imprecision and ROB)	Bamlanivimab/etesevi mab in combination reduce need of hospitalization compared to placebo
Casirivim ab/imdevi mab ²¹	41.6 po 1000	er 11.6 per 1000 (from 7.0 to 19.1)	0.28 (0.17/0.4 6)	3495 (2 RCT)	⊕⊕⊖⊝ low (downgraded for ROB and imprecision due to low number of events)	Casirivimab/imdevima b in combination reduce need of hospitalization compared to placebo
Bebtelovi mab- BLAZE- 4 ¹²	15.6 po 1000	15.9 per 1000 (from 2.1 to 115)	1.02 (0.14/7.3 9)	253 (1 RCT)	⊕⊕⊖⊝ low (downgraded twice for serious imprecision)	Bebtelovimab does not reduce need of hospitalization compared to placebo

Regdanvi mab-CT- P59 ²³ Tixagevi	86.5 1000 89.1	per	42.3 per 1000 (from 16.4 to 109) 41.8 per 1000	0.49 (0.19/1.2 7)	307 (1 RCT) 822 (1)	⊕⊕⊖ low (downgraded for ROB and imprecision) ⊕⊕⊕⊖	It is unclear if regdanvimab reduces hospitalization compared to placebo
mab— cilgavima b- TACKLE ²	1000	•	(from 24 to 74.7)	(0.27/0.8 4)		moderate (downgraded for imprecision)	Tixagevimab- cilgavimab reduces hospitalization compared to placebo in unvaccinated adults
mAbs: combined results	55.1 1000	per	17.6 per 1000 (from 13.2 to 23.1)	0.32(0.24 /0.42)	7411 (8 trials)	⊕⊕⊕⊖ moderate (downgraded for ROB)	Anti-Spike mAbs reduce hospitalization compared to placebo
Small molec		virals		T	T		
Molnupira vir ^{8, 25, 26}	11.8 1000	per	10.8 per 1000 (from 8.6 to 13.4)	0.91 (0.73/1.1 4)	27628 (3 RCTs)	⊕⊕⊖⊝ low (downgraded for inconsistency and imprecision)	It is unclear if Molnupiravir reduces hospitalization compared to placebo
Nirmatrel vir/ritonav ir ⁷	63 per	1000	7.5 per 1000 (from 3.7 to 15.1)	0.12 (0.06/0.2 4)	2085 (1)	⊕⊕⊖ low (downgraded for ROB and imprecision)*	Nirmatrelvir/ritonavir reduces hospitalization compared to placebo in unvaccinated adults
Remdesivi r ²⁷	53 per	1000	6.8 per 1000 (from 1.5 to 50.2)	0.13 (0.03/0.5 7)	562 (1)	⊕⊕⊖⊝ low (downgraded for ROB and imprecision)	Remdesivir reduces hospitalization compared to placebo
Favipiravi r ³²	16.8 1000	per	55.6 per 1000 (from 10.9 to 281)	3.31 (0.65/16. 76)	231 (1)	⊕⊕⊖ low (downgraded for serious imprecision)	Favipiravir does not reduce need of hospitalization compared to placebo
Peg- interferon lambda ^{28,} ^{29, 30}	54.5 1000	per	26.7 per 1000 (from 16.8 to 47.5)	0.49 (0.31/0.7 8)	2116 (3 RCTs)	⊕⊕⊕⊝ moderate (downgraded for ROB)	-Peginterferon lambda reduces hospitalization compared to placebo.

Sofosbuvi r and daclatasvi r- SOVODA K ³¹	142.8 1000	per	32.8 per 1000 (from 2.8 to 315)	0.23 (0.02/2.2 1)	55 (1)	⊕⊕⊖⊝ low (downgraded for serious imprecision)	It is unclear if sofosbuvir/daclatasvir reduces hospitalization compared to placebo
Lopinavir/ ritonavir- TOGETH ER ³³	48.4 1000	per	58 per 1000 (from 25.6 to 130.1)	1.20 (0.53/2.6 9)	471 (1)	⊕⊕⊖⊝ low (downgraded for serious imprecision)	Lopinavir/ritonavir does not reduce need of hospitalization compared to placebo
Small molecule antivirals: combined results	19.3 1000	per	12.5 per 1000 (from 10.4 to 15)	0.65 (0.54/0.7 8)	33148 (11)		-Antivirals reduce rate of hospitalization compared to placebo
Repurposed							
Metformi n- COVID- OUT ¹³	31.6 1000	per	13.2 per 1000 (from 5.6 to 30.3)	0.42 (0.18/0.9 6)	1197 (1)	⊕⊕⊖ low (downgraded for serious imprecision)	Metformin reduces hospitalization compared to placebo.
Fluvoxam ine ^{13, 34, 35}	96.3 1000	per	69.1 per 1000 (from 30.7 to 156.4)	0.72 (0.32/1.6 3)	2241 (3 RCTs)	⊕⊖⊖ very-low (downgraded for imprecision, inconsistency and ROB)	It is unclear if fluvoxamine reduces hospitalization compared to placebo
Ivermecti n ^{13, 36, 37, 38}	64.4 1000	per	60.5 per 1000 (from 47 to 78.5)	0.94(0.73 /1.22)	4228 (4 RCTs)	⊕⊕⊕⊝ moderate (downgraded for imprecision)	-It is unclear if Ivermectin reduces rate of hospitalization compared to placebo
Hydroxyc hloroquin e ^{33, 39, 40, 41,}	41.9 1000	per	31 per 1000 (from 18.8 to 51.5)	0.74 (0.45/1.2 3)	1536 (5 RCTs)	⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	It is unclear if hydroxychloroquine reduces hospitalization compared to placebo
Nitazoxan ide- Romark ⁴³	25.6 1000	per	5.3 per 1000 (from 0.5 to 45.8)	0.21 (0.02/1.7 9)	379 (1)	⊕⊖⊖ very-low (downgraded for serious imprecision and ROB)	It is unclear if nitazoxanide reduces

							1
							hospitalization
G 1 1 : :	50.1		45.0 1000	0.70	270 (1)	***	compared to placebo
Colchicin	58.1	per	45.8 per 1000	0.79	379 (1)	$\oplus \oplus \ominus \ominus$	It is unclear if
e-	1000		(from 35.4 to	(0.61/1.0		moderate (downgraded	colchicine reduces
COLCOR			59.8)	3)		for imprecision-95% CI	hospitalization
ONA ⁴⁴	•••				/1>	includes line of no effect)	compared to placebo
Niclosami	29.4	per	9.5 per 1000	0.33	67 (1)	$\oplus \oplus \ominus \ominus$ low	It is unclear if
de^{45}	1000		(from 0.29 to	(0.01/8.4)		(downgraded for serious	niclosamide reduces
			249)	8)		imprecision)	hospitalization
							compared to placebo
aspirin	7.3	per	6.8 per 1000	0.94	280 (1)	⊕⊖⊖⊖ very-low	Aspirin does not reduce
	1000		(from 0.4 to	(0.06/15.		(downgraded for serious	need of hospitalization
			11)	2)		imprecision and	compared to placebo
						indirectness)	1 1
apibaxan	7.3	per	7.3 per 1000	1.0	414 (2	⊕⊖⊖⊖ very-low	Apibaxan 2.5-5 mg
	1000		(from 1 to 52)	(0.14/7.1	arms)	(downgraded for serious	does not reduce need of
				8)		imprecision and	hospitalization
						indirectness)	compared to placebo
Sulodexid	294	per	223.4 per	0.52	243 (1)	$\oplus \oplus \oplus \ominus$	Sulodexide reduces
e ⁴⁷	1000		1000 (from	(0.28/0.9)		moderate (downgraded	hospitalization
			82.3 to 279.3)	5)		for imprecision)	compared to placebo
Enoxapari	56.8	per	60.2 per 1000	1.06	691 (2)	$\oplus \oplus \ominus \ominus$ low	LMW heparin does not
n-LMW	1000		(from 31.8 to	(0.56/2.0		(downgraded for serious	reduce hospitalization
heparin ^{48,}			115.3)	3)		imprecision)	compared to placebo
49							compared to pracedo
Inhaled	112	per	128.8 per	1.15	217 (1)	⊕⊖⊖⊖ very-low	Inhaled ciclesonide
ciclesonid	1000		1000 (from	(0.51/2.6)		(downgraded for serious	does not reduce need of
e ⁵⁰			57.1 to 294.5)	3)		imprecision and ROB)	hospitalization
							compared to placebo
Saliravira ⁵	285	per	133.9 per	0.47	143 (1)	⊕⊖⊖ very-low	Saliravira reduces
1	1000		1000 (from	(0.29/0.7		(downgraded for serious	hospitalization
			82.6 to 220.2)	7)		imprecision and serious	compared to control
		_				ROB)	compared to control

Azithrom	77.6 per	85.3 per 1000	1.10	489 (2)	$\oplus \oplus \ominus \ominus$ low	azithromycin does not
ycin ^{52, 53}	1000	(from 43.4 to	(0.56/2.1)		(downgraded for serious	reduce hospitalization
		169.1)	8)		imprecision)	compared to placebo
Resveratr	60 per 1000	19.2 per 1000	0.32	100(1)	$\oplus \oplus \ominus \ominus$ low	It is unclear if
ol ⁵⁴		(from 1.8 to	(0.03/3.1		(downgraded for serious	resveratrol reduces
		190.8)	8)		imprecision)	hospitalization
						compared to placebo
Repurpose	64.9 per	50 per 1000	0.77	16840	$\oplus \oplus \oplus \ominus$	Repurposed treatments
d drugs	1000	(from 44.1 to	(0.68/0.8)	(27 arms,	moderate (downgraded	reduce rate of
combined		57.1)	8)	15	for ROB)	
results				comparis		hospitalization compared to placebo
				ons)		compared to pracedo

^{*}The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect (the Risk Difference, also called ARR, absolute risk reduction)of the intervention (and its 95% CI).

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

Footnote: OR, Odds Ratio; CIs, confidence intervals; ROB, risk of bias. GRADE, Grading of Recommendations, Assessment, Development and Evaluations

Supplementary Table 2 Additional baseline data from RCTs

								symptoms	symptoms	symptoms	symptoms
	Enrollment	Study			age over	age over	age over	<= 8 days	<=7 days	<= 5 days	<= 3 days
Study	Period	months	Geography	Enrolled	65 n(%)	60 n(%)	50 n(%)	n(%)	n(%)	n(%)	n(%)
	Nov 10										
	2020 -July										
CCP-CONV-ert ¹⁶	28 2021	9	Spain	376			376 (100)		376 (100)		
CCP-COV-Early ¹⁹			Netherlands	406			351 (86)		406 (100)		
	Aug 2020-										
CCP-C3PO ¹⁵	Feb 2021	7	USA	511			511 (100)		511 (100)		246 (48)
	Jun 4 2020										
	- Oct 25										
CCP-Argentina ¹⁴	2020	5	Argentina	160	160 (100)						160 (100)
	June 3										
	2020-Oct							1181			
CCP-CSSC-004 ¹¹	2021	16	USA	1225	80 (7)		410 (35)	(100)		517 (44)	
	June 2020-									226	
Bamlanivimab-BLAZE-1 ²	Aug 2020	3	USA	467	53 (12)					(50)mean	
			United								
			States,								
	Aug 27		Canada,								
Sotrovimab-COMET-	2020-		Brazil, and							1057	
ICE ²³	March 2021	6	Spain	1057	211(20)					(100)	624 (59)
Bamlanivimab/etesevimab-	Sept 2020-										
BLAZE-1 ³	Dec 2020	3	USA	1035	323 (31)			979 (95)			
	Sept 24										
Casirivimab/ imdevimab-	2020-Jan 17		USA						2696		
REGEN-COV Ph 3 ²¹	2021	4	Mexico	2696	358 (13)				(100)		1489 (66)
	June 16,										
Casirivimab/ imdevimab-	2020 - Sept										
REGEN-COV Ph 1/2 ²⁰	23, 2020	3	USA	799					799 (100)	599 (75)	400 (50)
	May 2021-										
Bebtelovimab-BLAZE-4 ¹²	July 2021	3	USA	253	1 (<1)				253 (100)		

	1	1	I	I	1	I				
			South							
			Korea,							
	Oct 2020-		Romania,							
Regdanvimab-CT-P59 ²³	Dec 2020	2	Spain, USA	327		85 (26)		327 (100)		
			USA, Latin							
	Jan 28,		America,							
Tixagevimab-cilgavimab-	2021- July		Europe, and							
TACKLE ²⁴	22, 2021,	6	Japan.	1014	116 (13)			910 (100)		
Molnupiravir-MOVe-	May 2021-		•						1408	
OUT ⁷	Oct 2021	6	worldwide	1433		246 (17)			(100)	674 (48)
	Dec 8-2021		W STIGWTO	1.00		2.0 (17)			(100)	071(10)
Molnupiravir-	- April 27,								22510	
PANORAMIC ²⁵	2022	5	UK	25783	6838 (27)				(87)	
THIORNING	July 1, 2021	J	OK	23763	0030 (21)				(67)	
	- Aug 24,									
Molnupiravir-Aurobindo ²⁷	2021 - Aug 24,	2	India	1220						661 (54)
Nirmatrelvir/ritonavir-			Ilidia	1220					2246	` '
	July 1 2021			2246	207(12.0)				2246	1489
EPIC-HR ⁷	- Dec 2021	6	worldwide	2246	287(12.8)				(100)	(66.3)
			USA,							
			Spain,							
	Sept 2020-		Denmark							
Remdesivir-PINETREE ²⁷	Apr 2021	8	UK	562		170 (30)		562 (100)		
Interferon Lambda-	July 6 2021-									
TOGETHER ³⁰	March 2022	15	Brazil	1936						
	May 18,									
Interferon Lambda-	2020-Sep 4									
ILIAD ²⁸	2020	4	Canada	60				60 (100)		
	Apil 25									
Interferon Lambda-	2020-July 7									
COVID-Lambda ²⁹	2020	2	USA	120						
	April 8									
Sofosbuvir and daclatasvir-	2020-May									
SOVODAK ³¹	19 2020	1	Iran	55						
50 (OD/11)	17 2020	1 1	11411	1 33	1	l .		l	l .	

	ı			1		ı	1	1	1	1
	July 23,									
	2020- Aug		Saudi							
Favipiravir-Avi-Mild-19 ³²	4 2021	12	Arabia	245		30 (13)			231 (100)	
	June 2									
Lopinavir/ritonavir-	2020-Oct 9									
TOGETHER ³³	2020	4	Brazil	471		275	471 (100)		74 (16)	
	Dec 30	-		.,.			1,1 (100)		, 1 (10)	
	2020 - Jan							1197		
Metformin-COVID-OUT ¹³	28 2022	13	USA	1323				(100)		
		13	USA	1323				` ′		
Fluvoxamine-	Jan 2021 -	0	- ·	4.40		655 (AA)		1497		(20 (42)
TOGETHER ³⁵	Aug 2021	8	Brazil	1497		655 (44)		(100)		638 (43)
	April 10									
Fluvoxamine -STOP	2020 - Aug									
COVID ³⁶	5 2020	4	USA	152				152 (100)	114 (75)	
	Dec 30									
Fluvoxamine-COVID-	2020 - Jan									
OUT ¹³	28 2022	13	USA	661				733 (100)		
	March 23 -							1358		
Ivermectin-TOGETHER ³⁷	Aug 2 2021	5	Brazil	1358				(100)		597 (44)
	Dec 30		Breezn	1550				(100)		557 (1.1)
	2020 - Jan									
Ivermectin-COVID-OUT ¹³	28 2022	13	USA	808				592 (100)		
TVCIIICCUII-CO VID-OC I	Feb 19 21 -	13	USA	000				392 (100)		
Ivermectin Iran ³⁸		_		500						201 (50)
Ivermectin Iran	Aug 30 21	7	iran	582						291 (50)
	June 23									
	2021 - Feb									
Ivermectin-ACTIV-6	4 2022	7	USA	1591		680 (43)	1193 (75)			
	June 2									
Hydroxychloroquine-	2020-Oct 9									
TOGETHER ³⁴	2020	4	Brazil	441		262 (59)	441 (100)		77 (17)	
	March 22									
Hydroxychloroquine-	2020 - May		USA							
COVID-19 PEP ⁴²	20 2020	2	canada	491		99 (20)			423 (100)	
	_3 _0_0		- Januara			// (2 0)	1	l .	.23 (100)	l

	1	T	1	I	I	1	I	1	1	T	
	April 15										
Hydroxychloroquine -AH	2020 -May										
COVID-19 ⁴¹	22 2020	1	Canada	148							
	March 17										
Hydroxychloroquine-BCN	2020-May										
PEP-CoV-2 ⁴⁰	26 2020	2	Spain	293						293 (100)	
	April 15										
Hydroxychloroquine-	2020-July										
BMG ⁴³	27 2020	3	USA	231		23 (10)			143 (62)	85 (37)	
	Aug 2020-		USA Peurto	_		- (-)			- (-)		
Nitazoxanide-Romark ⁴³	Jan 2021	5	rico	379							379 (100)
Trivazentania Trentania	0.0012021		Brazil,	575							277 (100)
			Canada,								
			Greece,								
			South								
	March		Africa,								
Colchicine-	2020-Dec		Spain, and								
COLCORONA ⁴⁴	2020-Dec	9	the USA	4488		1122 (25)		3590 (80)			
COLCORONA		9	the USA	4400		1122 (23)		3390 (80)			
	Oct 1 2020-										
37: 1 : 1 45	April 20	_	***	=-							(5 (100)
Niclosamide ⁴⁵	2021	7	USA	73							67 (100)
	Sept 1 2020										
	- June 17										
aspirin-ACTIV-4B ⁴⁶	2021	10	USA	328		~82 (25)				82 (25)	
	Sept 1 2020										
2.5-mg apixaban-ACTIV-	- June 17										
4B ⁴⁶	2021	10	USA	329		~82 (25)				82 (25)	
	Sept 1 2020										
5-mg apixaban ACTIV-	- June 17										
$4B^{46}$	2021	10	USA	328		~82 (25)				82 (25)	
	June 5 2020										
	- August 5										
Sulodexide ⁴⁷	2020	2	Mexico	243							243 (100)

			~		1	1				
			Belgium,							
			Brazil,							
			India, South							
	Oct 27 2020		Africa,							
	- Nov 8		Spain, and							
Enoxaparin-ETHIC ⁴⁹	2021	12	the UK).	219			164 (75)		121 (50)	
	Aug 5		Switzerland							
	2020-Jan 14		and						429 (dx	
Enoxaparin-OVID ⁵⁰	2022	17	Germany	572			572 (100)		75)	
	Dec 29									
Inhaled ciclesonide-	2020-July									
COVERAGE ⁵⁰	22 2021	7	France	217		151 (70)	217 (100)	217 (100)		
	Dec 21									
	2020 -									
	March 1									
Saliravira ⁵¹	2021	3	Iran	143						
	June 3,									
	2020- Jan									
Azithromycin-Atomic2 ⁵²	29, 2021,	8	UK	292						
•	May 22									
	2020 -									
	March 16									
Azithromycin-ACTION ⁵³	2021	9	USA	197		18 (9)		197 (100)		
•	September					, ,		` ′		
	13, 2020 -									
	December									
Resveratrol ⁵⁴	11, 2020,	3	USA	100	16 (16)				50 (50)	

Supplementary Table 3 Hospitalized Odds Ratio statistics

Study	Hospitalization Odds ratio	Hospitalization 95 CI low	Hospitalization 95 CI high	Hospitalization significance (p)	Hospitalization z statistic
Total CCP	0.71	0.55	0.91	0.0035	2.697265
Total mAb	0.32	0.24	0.42	P<0.001	8.213656
Total antivirals	0.65	0.55	0.77	P<0.001	4.814847
Total repurposed	0.76	0.66	0.88	P<0.001	3.953106
Total	0.65	0.59	0.71	P<0.001	9.021468
CCP-CONV-ERT ¹⁶	1.05	0.56	1.99	0.4356	0.162033
CCP-CoV-Early ¹⁹	0.61	0.29	1.30	0.1021	1.269694
CCP-C3PO ¹⁵	0.90	0.59	1.37	0.3078	0.502004
CCP-Argentina ¹⁴	0.43	0.20	0.91	0.0140	2.197789
CCP-CSSC-004 ¹¹	0.44	0.25	0.79	0.0031	2.737543
CCP-Argentina (high					
titer) ¹⁴	0.20	0.06	0.71	0.0132	2.478
CCP-CSSC-004 (<= 5					
days) 11	0.18	0.07	0.49	0.0007	3.38
Bamlanivimab-BLAZE-1 ²	0.24	0.08	0.74	0.0066	2.479993
Sotrovimab-COMET-					
ICE ²³	0.19	0.08	0.46	0.0001	3.663844
Bamlanivimab/etesevimab-					
BLAZE-1 ³	0.29	0.15	0.58	0.0002	3.534471
Casirivimab/ imdevimab-					
REGEN-COV Ph 3 ²¹	0.28	0.16	0.47	0.0000	4.734662
Casirivimab/ imdevimab-					
REGEN-COV Ph 1/2 ²⁰	0.30	0.07	1.25	0.0484	1.660556
Bebtelovimab-BLAZE-4 ¹²	1.02	0.14	7.39	0.4905	0.023906
Regdanvimab-CT-P59 ²³	0.49	0.19	1.27	0.0716	1.463817

Tixagevimab-cilgavimab-					
TACKLE ²⁴	0.47	0.26	0.84	0.0057	2.528551
Molnupiravir-MOVe-					
OUT ⁷	0.67	0.46	0.99	0.0223	2.00829
Molnupiravir-					
PANORAMIC ²⁵	1.07	0.81	1.42	0.3156	0.479984
Molnupiravir-Aurobindo ²⁷	NA	NA	NA	NA	NA
Nirmatrelvir/ritonavir-					
EPIC-HR ⁷	0.12	0.06	0.24	0.0000	5.731691
Remdesivir-PINETREE ²⁷	0.13	0.03	0.57	0.0034	2.703067
Interferon Lambda-					
TOGETHER ³⁰	0.47	0.29	0.77	0.0011	3.054966
Interferon Lambda-					
ILIAD ²⁸	1.00	0.06	16.76	0.5000	0
Interferon Lambda-					
COVID-Lambda ²⁹	1.00	0.14	7.34	0.5000	0
Sofosbuvir and daclatasvir-		0.00		0.4040	1.051414
SOVODAK ³¹	0.23	0.02	2.21	0.1018	1.271414
Favipiravir-Avi-Mild-19 ³²	3.31	0.65	16.76	0.0739	1.44706
Lopinavir/ritonavir-	1.20	0.52	2.60	0.2222	0.420026
TOGETHER ³³	1.20	0.53	2.69	0.3333	0.430926
Metformin-COVID-OUT ¹³	0.42	0.18	0.96	0.0198	2.057
Fluvoxamine- TOGETHER ³⁵	0.77	0.56	1.05	0.0505	1.640023
Fluvoxamine -STOP	0.77	0.36	1.05	0.0303	1.040023
COVID ³⁶	0.06	0.00	1.15	0.0310	1.866043
Fluvoxamine-COVID-	0.00	0.00	1.13	0.0310	1.000043
OUT ¹³	1.18	0.36	3.91	0.3935	0.270145
Ivermectin-TOGETHER ³⁷	0.87	0.65	1.18	0.1831	0.903781
Ivermectin-COVID-OUT ¹³	0.76	0.20	2.85	0.3414	0.408715
Ivermectin Iran ³⁸	1.46	0.71	2.96	0.1507	1.033341
Ivermectin-ACTIV-6 ³⁹	1.05	0.43	2.61	0.4553	0.112309
Hydroxychloroquine-					
TOGETHER ³⁴	0.76	0.30	1.93	0.2840	0.570928

Hydroxychloroquine-					
COVID-19 PEP ⁴²	0.49	0.16	1.45	0.0971	1.298164
Hydroxychloroquine -AH					
COVID-19 ⁴¹	3.14	0.17	59.70	0.2232	0.761332
Hydroxychloroquine-BCN					
PEP-CoV-2 ⁴⁰	0.83	0.32	2.13	0.3486	0.389184
Hydroxychloroquine-					
BMG ⁴³	0.69	0.18	2.65	0.2945	0.54027
Nitazoxanide-Romark ⁴³	0.21	0.02	1.79	0.0766	1.428571
Colchicine-					
COLCORONA ⁴⁴	0.79	0.61	1.03	0.0407	1.742726
Niclosamide ⁴⁵	0.33	0.01	8.48	0.2529	0.665353
Aspirin-ACTIV-4B ⁴⁶	0.94	0.06	15.24	0.4838	0.040562
2.5-mg apixaban-ACTIV-					
$4B^{46}$	1.01	0.06	16.27	0.4979	0.005238
5-mg apixaban ACTIV-					
$4B^{46}$	1.91	0.17	21.36	0.2988	0.527902
Sulodexide ⁴⁷	0.52	0.28	0.95	0.0167	2.128119
Enoxaparin-ETHIC ⁴⁹	1.10	0.47	2.56	0.4155	0.213485
Enoxaparin-OVID ⁵⁰	1.02	0.38	2.76	0.4862	0.034489
Inhaled ciclesonide-					
COVERAGE ⁵⁰	1.15	0.51	2.63	0.3659	0.34277
Saliravira ⁵¹	0.01	0.00	0.24	0.0016	2.9467
Azithromycin-Atomic2 ⁵²	0.88	0.42	1.84	0.3694	0.333472
Azithromycin-ACTION ⁵³	6.62	0.36	121.45	0.1015	1.272994
Resveratrol ⁵⁴	0.32	0.03	3.18	0.1654	0.972432

Supplementary Table 4 Deaths during RCTs

		95% CI	95% CI	Odds	95 CI	95 CI	Z	significance
ARR%	RRR%				low		statistic	(p)
		(-0.48,						
0.15	20	0.78)	68.4)	0.80	0.31	2.02	0.4785	0.3162
		(0.23,	(52.0,					
0.51	84	0.79)	94.3)	0.16	0.06	0.48	3.3107	0.0005
		(0.06,	(42.6,					
0.13	75	0.20)	89.0)	0.25	0.11	0.57	3.2733	0.0005
		(-0.02,	(-2.3,					
0.24	28	0.50)	49.6)	0.72	0.5	1.02	1.8362	0.0332
		(0.11,	(28.4,					
0.20	46	0.30)	59.7)	0.54	0.4	0.72	4.2423	1E-05
				Total	%			
Deaths	Total	Deaths	Total	both	death	% death		
control	control	intervent.	intervent.	arms	control	intervent.		
10	1315	8	1319	2634	0.76	0.61		
21	3443	4	3978	7421	0.61	0.10		
28	16606	7	16542	33148	0.17	0.04		
72	8316	53	8524	16840	0.87	0.62		
131	29680	72	30363	60043	0.44	0.24		
2	188	0	188	376	1.06	0.00		
0	204	1	202	406	0.00	0.50		
1	254		257	511	0.39	1.95		
4	80	2	80	160	5.00	2.50		
3	589	0	592	1181	0.51	0.00		
0	143	0	309	452	0.00	0.00		
2	529	0	528	1057	0.38	0.00		
10	517	0	518	1035	1.93	0.00		
	0.15 0.51 0.13 0.24 0.20 Deaths control 10 21 28 72 131 2 0 1 4 3 0 2	0.15 20 0.51 84 0.13 75 0.24 28 0.20 46 Deaths control Total control 10 1315 21 3443 28 16606 72 8316 131 29680 2 188 0 204 1 254 4 80 3 589 0 143 2 529	ARR% RRR% ARR 0.15 20 0.78) (0.23, 0.51 84 0.79) (0.06, 0.20) (-0.02, 0.24 28 0.50) (0.11, 0.30) Deaths control Total control Deaths intervent. 10 1315 8 21 3443 4 28 16606 7 72 8316 53 131 29680 72 2 188 0 0 204 1 1 254 5 4 80 2 3 589 0 0 143 0 2 529 0	ARR% RRR% ARR (-0.48, (-101, 0.15) 0.78) (68.4) 0.15 20 0.78) 68.4) 0.51 84 0.79) 94.3) 0.13 75 0.20) 89.0) 0.24 28 0.50) 49.6) 0.20 46 0.30) 59.7) Deaths control Total control intervent. Total intervent. 10 1315 8 1319 21 3443 4 3978 28 16606 7 16542 72 8316 53 8524 131 29680 72 30363 2 188 0 188 0 204 1 202 1 254 5 257 4 80 2 80 3 589 0 592 0 143 0 309 2 529 0 528	ARR% RRR% (-0.48, (-101, 0.80) 0.15 20 0.78) 68.4) 0.80 0.51 84 0.79) 94.3) 0.16 0.13 75 0.20) 89.0) 0.25 0.24 28 0.50) 49.6) 0.72 0.20 46 0.30) 59.7) 0.54 Deaths control Total control intervent. Total intervent. both intervent. 10 1315 8 1319 2634 21 3443 4 3978 7421 28 16606 7 16542 33148 72 8316 53 8524 16840 131 29680 72 30363 60043 2 188 0 188 376 0 204 1 202 406 1 254 5 257 511 4 80 2 80 160 3	ARR% RRR% ratio low 0.15 20 0.78) 68.4) 0.80 0.31 0.51 84 0.79) 94.3) 0.16 0.06 0.13 75 0.20) 89.0) 0.25 0.11 0.24 28 0.50) 49.6) 0.72 0.5 0.20 46 0.30) 59.7) 0.54 0.4 Total control control intervent. Deaths intervent. Total intervent. both death control control intervent. 10 1315 8 1319 2634 0.76 21 3443 4 3978 7421 0.61 28 16606 7 16542 33148 0.17 72 8316 53 8524 16840 0.87 131 29680 72 30363 60043 0.44 2 188 0 188 376 1.06 0 204 1 202	ARR% RRR% RRR ratio low high 0.15 20 0.78) 68.4) 0.80 0.31 2.02 0.51 84 0.79) 94.3) 0.16 0.06 0.48 0.13 75 0.20) 89.0) 0.25 0.11 0.57 0.24 28 0.50) 49.6) 0.72 0.5 1.02 0.20 46 0.30) 59.7) 0.54 0.4 0.72 Deaths control Total intervent. both death control intervent. w death intervent. w death intervent. 10 1315 8 1319 2634 0.76 0.61 21 3443 4 3978 7421 0.61 0.10 28 16606 7 16542 33148 0.17 0.04 72 8316 53 8524 16840 0.87 0.62 131 29680 72 30363 60043 <td>ARR% RRR% RRR ratio low high statistic 0.15 20 0.78) 68.4) 0.80 0.31 2.02 0.4785 0.51 84 0.79) 94.3) 0.16 0.06 0.48 3.3107 0.13 75 0.20) 89.0) 0.25 0.11 0.57 3.2733 0.24 28 0.50) 49.6) 0.72 0.5 1.02 1.8362 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 1315 8 1319</td>	ARR% RRR% RRR ratio low high statistic 0.15 20 0.78) 68.4) 0.80 0.31 2.02 0.4785 0.51 84 0.79) 94.3) 0.16 0.06 0.48 3.3107 0.13 75 0.20) 89.0) 0.25 0.11 0.57 3.2733 0.24 28 0.50) 49.6) 0.72 0.5 1.02 1.8362 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 46 0.30) 59.7) 0.54 0.4 0.72 4.2423 0.20 1315 8 1319

Casirivimab/ imdevimab-							
REGEN-COV Ph 3 ²¹	3	1341	1	1355	2696	0.22	0.07
Casirivimab/ imdevimab-							
REGEN-COV Ph 1/2 ²⁰	0	266	0	533	799	0.00	0.00
Bebtelovimab-BLAZE-4 ¹²	0	128	0	125	253	0.00	0.00
Regdanvimab-CT-P59 ²³	0	104	0	203	307	0.00	0.00
Tixagevimab-cilgavimab-							
TACKLE ²⁴	6	415	3	407	822	1.45	0.74
Molnupiravir-MOVe-OUT ⁷	9	699	1	709	1408	1.29	0.14
Molnupiravir-							
PANORAMIC ²⁵	5	12484	2	12516	25000	0.04	0.02
Molnupiravir-Aurobindo ²⁷	0	610	0	610	1220	0.00	0.00
Nirmatrelvir/ritonavir-EPIC-							
HR ⁷	12	1046	0	1039	2085	1.15	0.00
Remdesivir-PINETREE ²⁷	1	283	0	279	562	0.35	0.00
Interferon Lambda-							
TOGETHER ³⁰	1	1020	4	916	1936	0.10	0.44
Interferon Lambda- ILIAD ²⁸	0	30	0	30	60	0.00	0.00
Interferon Lambda-COVID-							
Lambda ²⁹	0	60	0	60	120	0.00	0.00
Sofosbuvir and daclatasvir-							
SOVODAK ³¹	0	28	0	27	55	0.00	0.00
Favipiravir-Avi-Mild-19 ³²	0	119	0	112	231	0.00	0.00
Lopinavir/ritonavir-							
TOGETHER ³³	0	227	0	244	471	0.00	0.00
Metformin-COVID-OUT ¹³	1	601	1	596	1197	0.17	0.17
Fluvoxamine-TOGETHER ³⁵	25	756	17	741	1497	3.31	2.29
Fluvoxamine -STOP							
COVID ³⁶	0	72	0	80	152	0.00	0.00
Fluvoxamine-COVID-							
OUT ¹³	0	293	0	299	592	0.00	0.00
Ivermectin-TOGETHER ³⁷	24	675	21	674	1349	3.56	3.12

Incompacting COVID OUT13	0	256	1	274	720	0.00	0.27
Ivermectin-COVID-OUT ¹³	0	356	1	374	730		0.27
Ivermectin Iran ³⁸	1	281	1	268	549	0.36	0.37
Ivermectin-ACTIV-6 ³⁹	0	774	1	817	1591	0.00	0.12
Hydroxychloroquine-							
TOGETHER ³⁴	1	227	0	214	441	0.44	0.00
Hydroxychloroquine-							
COVID-19 PEP ⁴²	1	211	1	212	423	0.47	0.47
Hydroxychloroquine -AH							
COVID-19 ⁴¹	0	37	0	111	148	0.00	0.00
Hydroxychloroquine-BCN							
PEP-CoV-2 ⁴⁰	0	157	0	136	293	0.00	0.00
Hydroxychloroquine-BMG ⁴³	0	83	0	148	231	0.00	0.00
Nitazoxanide-Romark ⁴³	0	195	0	184	379	0.00	0.00
Colchicine-COLCORONA ⁴⁴	9	2253	5	2235	4488	0.40	0.22
Niclosamide ⁴⁵	0	34	0	33	67	0.00	0.00
Aspirin-ACTIV-4B ⁴⁶	0	136	0	144	280	0.00	0.00
2.5-mg apixaban-ACTIV-							
$4B^{46}$	0	136	0	135	271	0.00	0.00
5-mg apixaban ACTIV-4B ⁴⁶	0	136	0	143	279	0.00	0.00
Sulodexide ⁴⁷	7	119	3	124	243	5.88	2.42
Enoxaparin-ETHIC ⁴⁹	0	114	1	105	219	0.00	0.95
Enoxaparin-OVID ⁵⁰	0	238	0	234	472	0.00	0.00
Inhaled ciclesonide-							
COVERAGE ⁵⁰	2	107	0	110	217	1.87	0.00
Saliravira ⁵¹	0	56	0	87	143	0.00	0.00
Azithromycin-Atomic2 ⁵²	1	147	1	145	292	0.68	0.69
Azithromycin-ACTION ⁵³	0	72	0	125	197	0.00	0.00
Resveratrol ⁵⁴	0	50	0	50	100	0.00	0.00

It is made available under a CC-BY-ND 4.0 International license .

Supplementary Figure 1 Risk of bias by RCT

					,			
			Deviations from	Missing outcome	Mesaurement of the	Selection of the	Overall risk of	
TYPE	Study	Radomization	intervention	data	outcome	reported results	bias	ROB Source
Ab-CCP	CCP-CONV-ert	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
Ab-CCP	CCP-COV-early							pending in NMA-COVID
Ab-CCP	CCP-C3PO	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
Ab-CCP	CCP-Argentina	Low	Low	Low	Low	Some concerns	Some concerns	https://covid-nma.com/
Ab-CCP	CCP-CSSC-004	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
Ab-CCF Ab-MONO	Bamlanivimab-BLAZE-1	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
				1				
Ab-MONO	Sotrovimab-COMET-ICE	Low	Low	Some concerns	Low	Some concerns	Some concerns	https://covid-nma.com/
Ab-MONO	BLAZE-1	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
	Casirivimab/imdevimab-	6		c				h.u
Ab-MONO	REGEN-COV Ph 3	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	https://covid-nma.com/
	Casirivimab/imdevimab-							,, ,
Ab-MONO	REGEN-COV Ph 1/2	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
Ab-MONO	Bebtelovimab-BLAZE-4	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
Ab-MONO	Regdanvimab-CT-P59	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
	Tixagevimab-cilgavimab-							
Ab-MONO	TACKLE	Low	Some concerns	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
DRUG-AV	Molnupiravir-MOVe-OUT	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
DRUG-AV	Molnupiravir-PANORAMIC	Low	Some concerns	HIGH	Some concerns	Low	HIGH	https://covid-nma.com/
DRUG-AV	Molnupiravir-Aurobindo	Low	Low	Low	Some concerns	Some concerns	Some concerns	https://covid-nma.com/
DRUG-AV	Nirmatrelvir/ritonavir-EPIC-HR	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
DRUG-AV	Remdesivir-PINETREE	Some concerns	Low	Low	Low	Low	Some concerns	https://covid-nma.com/
DRUG-AV	Interferon Lambda-TOGETHER							data not published Eiger
DRUG-AV	Interferon Lambda-ILIAD	Low	Low	Low	Low	Some concerns	Some concerns	https://covid-nma.com/
DRUG-AV	Interferon Lambda-COVID	Low	Low	Low	Low	Some concerns	Some concerns	https://covid-nma.com/
DRUG-AV	SOVODAK		little evidence to so					https://covid-nma.com/
						little evidence to score		
DRUG-AV	Favipiravir-Avi-Mild-19	Low	Low	Low	Some concerns	Low	Some concerns	https://covid-nma.com/
DRUG-AV	Lopinavir/ritonavir-TOGETHER	Low	Low	Some concerns	Low	Some concerns	Some concerns	https://covid-nma.com/
DRUG-RP	Metformin-COVID-OUT	Low	Low	Unclear	Low	Low	Low	RevMan pending in NMA-COVID
DRUG-RP	Fluvoxamine-TOGETHER	Low	Some concerns	Low	Low	Low	Some concerns	https://covid-nma.com/
DRUG-RP	Fluvoxamine -STOP COVID	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
500 III		LOW	LOW	Some concerns				,,,,
5.00 KI		LOW	LOW	Some concerns				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DRUG-RP	Fluvoxamine-COVID-OUT	Low	Low	Unclear	Low	Low	Low	RevMan pending in NMA-COVID
								RevMan pending in NMA-COVID Revman and
								RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co
								RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C
DRUG-RP	Fluvoxamine-COVID-OUT	Low	Low	Unclear	Low	Low	Low	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO
								RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C
DRUG-RP	Fluvoxamine-COVID-OUT	Low	Low	Unclear	Low	Low	Low	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.0 D015017.pub3/references#riskO fBias2
DRUG-RP DRUG-RP DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT	Low	Low	Unclear	Low	Low	Low	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.0 D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID
DRUG-RP	Fluvoxamine-COVID-OUT	Low	Low	Unclear	Low	Low	Low	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.0 D015017.pub3/references#riskO fBias2
DRUG-RP DRUG-RP DRUG-RP DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran	Low	Low	Unclear Unclear	Low	Low	Low	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID
DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6	Low Low Low	Low Low Low	Unclear Unclear Unclear	Low Low	Low Low Low	Low Low Unclear	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co pn/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID
DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER	Low Low Low	Low Low Low	Unclear Unclear Low Some concerns	Low Low Low	Low Low Low Some concerns	Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP	Low Low Low Low Some concerns	Low Low Low Low Low Low	Unclear Unclear Low Some concerns Some concerns	Low Low Low Low	Low Low Some concerns Low	Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER	Low Low Low	Low Low Low	Unclear Unclear Low Some concerns	Low Low Low	Low Low Low Some concerns	Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.0 D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP	Low Low Low Low Some concerns	Low Low Low Low Low	Unclear Unclear Low Some concerns Some concerns	Low Low Low Low	Low Low Some concerns Low	Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19	Low Low Low Low Some concerns	Low Low Low Low Low Low Low	Unclear Unclear Low Some concerns Some concerns Low	Low Low Low Low Low Low Low	Low Low Low Some concerns Low Some concerns	Low Low Unclear Some concerns Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/ https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2	Low Low Low Low Some concerns Low Low	Low Low Low Low Low Low Low Low	Unclear Unclear Low Some concerns Low Some concerns	Low Low Low Low Low Low Low Low Some concerns	Low Low Low Some concerns Low Some concerns Some concerns	Low Low Unclear Some concerns Some concerns Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID pending in NMA-COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 COVID-19 COV-2 Hydroxychloroquine-BMG	Low	Low	Unclear Unclear Low Some concerns Low Some concerns Low Some concerns	Low	Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns	Low Low Low Unclear Some concerns Some concerns Some concerns Some concerns Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA	Low	Low Low Low Low Low Low Low Low Low	Unclear Unclear Low Some concerns Some concerns Low Some concerns Some concerns Some concerns	Low	Low Low Low Some concerns Low Some concerns Some concerns Some concerns	Low Low Unclear Some concerns Some concerns Some concerns Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide	Low Low Low Some concerns Low Low Low Low Low Low Low Some concerns	Low	Unclear Unclear Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low Some concerns	Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns	Low Low Unclear Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin-Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B	Low Low Low Some concerns Low Low Low Low Low Low Low Low Low Some concerns	Low	Unclear Unclear Low Some concerns Low Some concerns Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Some concerns	Low Low Low Low Low Low Low Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low Low	Low Low Unclear Some concerns	RewMan pending in NMA-COVID Rewman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 COV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B	Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low	Unclear Unclear Low Some concerns	Low	Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low Low Low	Low Low Unclear Some concerns	RewMan pending in NMA-COVID Rewman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fBias2 RewMan pending in NMA-COVID pending in NMA-COVID RewMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 COV-2 Hydroxyhloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B 5-mg apixaban-ACTIV-4B	Low Low Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low Low Low	Unclear Unclear Unclear Low Some concerns Some concerns Low Some concerns Low Some concerns	Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low Low	Low Low Unclear Some concerns	RewMan pending in NMA-COVID Rewman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fbias2 RewMan pending in NMA-COVID pending in NMA-COVID RewMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2 Hydroxychloroquine-BMG Nitzaxxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B 5-mg apixaban-ACTIV-4B Sulodexide	Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low	Unclear Unclear Low Some concerns	Low	Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low Low Low	Low Low Unclear Some concerns	RewMan pending in NMA-COVID Rewman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RewMan pending in NMA-COVID pending in NMA-COVID RewMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B Sulodexide Enoxaparin-ETHIC	Low Low Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low Low Low	Unclear Unclear Unclear Low Some concerns Some concerns Low Some concerns Low Some concerns	Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low Low	Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 COV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Nitlosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B S-mg apixaban ACTIV-4B Sulodexide Enoxaparin-ETHIC Enoxaparin-OVID	Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low	Unclear Unclear Unclear Low Some concerns	Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low	Low Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.0 D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID pending in NMA-COVID
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B S-mg apixaban ACTIV-4B Sulodexide Enoxaparin-ETHIC Enoxaparin-OVID Inhaled ciclesonide-COVERAGE	Low Low Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low Low Low	Unclear Unclear Unclear Low Some concerns Some concerns Low Some concerns Low Some concerns	Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low Low	Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858. D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 COV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Nitlosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B S-mg apixaban ACTIV-4B Sulodexide Enoxaparin-ETHIC Enoxaparin-OVID	Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low	Unclear Unclear Unclear Low Some concerns	Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low	Low Low Low Unclear Some concerns	RevMan pending in NMA-COVID Revman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.0 D015017.pub3/references#riskO fBias2 RevMan pending in NMA-COVID pending in NMA-COVID RevMan pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID pending in NMA-COVID
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 CoV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B S-mg apixaban ACTIV-4B Sulodexide Enoxaparin-ETHIC Enoxaparin-OVID Inhaled ciclesonide-COVERAGE	Low Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low	Unclear Unclear Unclear Low Some concerns	Low	Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low	Low Low Low Unclear Some concerns	RewMan pending in NMA-COVID Rewman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.0 D015017.pub3/references#riskO fBias2 RewMan pending in NMA-COVID pending in NMA-COVID RewMan pending in NMA-COVID https://covid-nma.com/
DRUG-RP	Fluvoxamine-COVID-OUT Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 COV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B 5-mg apixaban-ACTIV-4B Sulodexide Enoxaparin-ETHIC Enoxaparin-THIC Enoxaparin-OVID Inhaled ciclesonide-COVERAGE Saliravira	Low Low Low Some concerns Low	Low Low Low Low Low Low Low Low Low Low	Unclear Unclear Unclear Low Some concerns Low Low Low Low Low Low Low Lo	Low Low Low Low Low Low Low Low Low Low	Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Low Low Unclear Some concerns Low	RewMan pending in NMA-COVID Rewman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fbias2 RewMan pending in NMA-COVID pending in NMA-COVID RewMan pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID
DRUG-RP DRUG-RP	Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 TOGETHER 19 PEP COVID-19 COV-2 Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Niclosamide Aspirin-ACTIV-4B Sulodexide Enoxaparin-ETHIC Enoxaparin-ETHIC Enoxaparin-CVID Inhaled ciclesonide-COVERAGE Saliravira Azithromycin-Atomic2	Low Low Low Some concerns Low Low Low Low Low Low Some concerns Low Low Low Low Low Low Low Lo	Low Low Low Low Low Low Low Low	Unclear Unclear Low Some concerns Some concerns Low Some concerns Some concerns Low Some concerns Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low	Low Low Low Low Low Low Low Low	Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low Low Low Low Low Low Low Lo	Low Low Unclear Some concerns Low Some concerns	RewMan pending in NMA-COVID Rewman and https://www.cochranelibrary.co m/cdsr/doi/10.1002/14651858.C D015017.pub3/references#riskO fBias2 RewMan pending in NMA-COVID pending in NMA-COVID RewMan pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID https://covid-nma.com/ pending in NMA-COVID

Supplementary Figure 2 Odds ratio for hospitalizations from all therapeutic interventions, ordered according to mechanism of action (CCP, anti-Spike mAbs, small molecule antivirals and repurposed drugs

Intervention			C	ontrol					
Study	Events	Total	Events	Total	Odds Ratio	OR	95	%-CI	Weight
COD CONN. EDT		400							0.00/
CCP-CONV-ERT	22	188	21	188	<u> </u>	1.05	[0.56;	-	3.0%
CCP-CoV-Early	12	202	19	204		0.61	[0.29;	-	2.6%
CCP-C3PO	52	257	56	254	_ = 1	0.90	[0.59;		3.7%
CCP-Argentina	13	80	25	80	-	0.43	[0.20;	-	2.6%
CCP-CSSC-004	17	592	37	589	-	0.44	[0.25;		3.1%
Bamlanivimab-BLAZE-1	5	309	9	143		0.24	[0.08;		1.8%
Sotrovimab-COMET-ICE	6	528	30	529		0.19	[0.08;	-	2.3%
Bamlanivimab/etesevimab-BLAZE-1	11	518	36	517	-	0.29	[0.15;		2.8%
Casirivimab/imdevimab-REGEN-COV Ph 3	18	1355	62	1341		0.28	[0.16;	-	3.3%
Casirivimab/imdevimab-REGEN-COV Ph 1/3		533	5	266	* :	0.30	[0.07;		1.3%
Bebtelovimab-BLAZE-4	2	125	2	128		1.02	[0.14;		0.8%
Regdanvimab-CT-P59	9	203	9	104	-	0.49	[0.19;	-	2.1%
Tixagevimab-cilgavimab-TACKLE	18	407	37	415		0.47	[0.26;		3.2%
Molnupiravir-MOVe-OUT	48	709	68	699		0.67	[0.46;		3.8%
Molnupiravir–PANORAMIC		12516		12484	 	1.07	[0.81;	1.42]	4.1%
Molnupiravir–Aurobindo	0	610	0	610					0.0%
Nirmatrelvir/ritonavir-EPIC-HR	8	1039	66	1046	-	0.12	[0.06;	-	2.7%
Remdesivir-PINETREE	2	279	15	283	***	0.13	[0.03;		1.2%
Interferon Lambda-TOGETHER	25	916	57	1020		0.47	[0.29;		3.5%
Interferon Lambda- ILIAD	1	30	1	30		— 1.00	[0.06;	-	0.4%
Interferon Lambda-COVID-Lambda	2	60	2	60	-	1.00	[0.14;		0.8%
Sofosbuvir and daclatasvir–SOVODAK	1	27	4	28	*	0.23	[0.02;	-	0.6%
Favipavir-Avi-Mild-19	6	112	2	119	*	— 3.31	[0.65;	-	1.0%
Lopinavir/ritonavir-TOGETHER	14	244	11	227	- •	1.20	[0.53;		2.5%
Metformin-COVID-OUT	8	596	19	601	-	0.42	[0.18;		2.4%
Fluvoxamine-TOGETHER	75	741	97	756	:•	0.77	[0.56;	-	4.0%
Fluvoxamine –STOP COVID	0	80	6	72	*	0.06	[0.00;		0.4%
Fluvoxamine-COVID-OUT	6	299	5	293		1.18	[0.36;		1.6%
Ivermectin=TOGETHER	95	674	107	675	-	0.87	[0.65;	-	4.0%
Ivermectin-COVID-OUT	4	374	5	356		0.76	[0.20;		1.4%
Ivermectin Iran	19	268	14	281	+-	1.46	[0.71;	-	2.7%
Ivermectin–ACTIV–6	10	817	9	774		1.05	[0.43;		2.2%
Hydroxychloroquine-TOGETHER	8	214	11	227		0.76	[0.30;		2.2%
Hydroxychloroquine-COVID-19 PEP	5	212	10	211	*	0.49	[0.16;		1.8%
Hydroxychloroquine –AH COVID–19	4	111	0	37	*		[0.17;		0.4%
Hydroxychloroquine-BCN PEP-CoV-2	8	136	11	157		0.83	[0.32;		2.1%
Hydroxychloroquine-BMG	5	148	4	83		0.69	[0.18;	-	1.4%
Nitazoxanide-Romark	1	184	5	195	*	0.21	[0.02;		0.7%
Colchicine-COLCORONA	104	2235	131	2253	" 	0.79	[0.61;	-	4.1%
Niclosamide	0	33	1	34	·	0.33	[0.01;	-	0.3%
Aspirin–ACTIV–4B	1	144	1	136	*	— 0.94	[0.06;		0.4%
2.5-mg apixaban-ACTIV-4B	1	135	1	136	<u> </u>	— 1.01	[0.06;		0.4%
5-mg apixaban ACTIV-4B	2	143	_ 1	136	*		[0.17; 2		0.5%
Sulodexide	22	124	35	119	-	0.52	[0.28;		3.1%
Enoxaparin-ETHIC	12	105	12	114		1.10	[0.47;		2.4%
Enoxaparin-OVID	8	234	8	238	*	1.02	[0.38;	-	2.0%
Inhaled ciclesonide–COVERAGE	14	110	12	107	-	1.15	[0.51;		2.4%
Saliravira	0	87	16	56	←	0.01	[0.00;	-	0.4%
Azithromycin–Atomic2	15	145	17	147		0.88	[0.42;		2.7%
Azithromycin–ACTION	5	125	0	72	•		[0.36; 12		0.4%
Resvertrol	1	50	3	50	*	0.32	[0.03;	3.18]	0.6%
_ , , ,		00000	4		[]		F0 F :		400
Random effects model	831	30363	1211	29680	*	0.62	[0.51;	0.74]	100.0%
Heterogeneity: $I^2 = 58\%$, $\tau^2 = 0.2085$, $p < 0.01$				_					
Test for overall effect: $z = -5.01$ ($p < 0.01$)				0.	.05 0.5 1 2 1	0 20			

It is made available under a CC-BY-ND 4.0 International license .

Supplementary Figure 3

Funnel plots by RCTs class A) CCP, B) anti-Spike mAbs C) small molecule antivirals and D) repurposed drugs. For anti-Spike mAbs RCTs, there is a suggestion of missing studies on the right side of the plot, where results would be unfavourable to the experimental intervention, for which either very high efficacy of high-dose anti-Spike mAbs or non-reporting bias is a plausible explanation.

